 
Document Type:  Study protocol  
Official Title:  Multicenter, randomized, placebo -controlled, double -blind, parallel 
group, dose -finding Phase  [ADDRESS_60947] N umber:  [STUDY_ID_REMOVED]  
Document D ate: 24-Oct-2019 
 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  1of 86
Title Page
Protocol Title: 
Multicenter, r andomized, placebo -controlled, double -blind, parallel group, dose -finding P hase 
2 study  to evaluate efficacy  and safet y of BAY 2433334 in patients following a n acute non-
cardioembolic ischemic stroke 
Protocol Number: [ZIP_CODE]
Amendment Number: not applicable
Compound Number: BAY 2433334
Study Phase: Phase 2b
Short Title: Phase 2 P rogram of AntiCoagulation via Inhibition of F XIa by 
[CONTACT_50906] C ompound BAY 2433334 – non-cardioembolic
STROKE study
Acronym: PACIFIC -STROKE
Sponso r Name [CONTACT_29560]:
Non-US: Bay er AG, [ZIP_CODE] L everkusen, [LOCATION_013] 
US territory : Bay er HealthCare Pharmaceuticals Inc., [ADDRESS_60948], [PO_BOX], 
Whippany  NJ [ZIP_CODE]- 0915, [LOCATION_003]
Regulatory Agency Identifier Number(s):
IND: [ADDRESS_60949]: 2019-003431-33
Approval Date: [ADDRESS_60950] 2019
Confidential
The information provided in this document is strictly confidential and is intended solely for the performance of 
the clinical investigation.  Reproduction or disclosure of this document, whether in part or in full, to parties not associated with the clinical investigation or its use for any other purpose w ithout the prior written consent of the 
sponsor is not permitted. 
Throughout this document, symbols indicating proprietary names (®, TM) may not be displayed. Hence, the 
appearance of product names withou t these symbols does not imply that these names are not protected.
CONFIDENTIAL 
Sponsor Signatory 
  
 Clinical Study Protocol 
No. BAY 2433334 / [ZIP_CODE] 
Version 1.0 
Date Page : 2 of 86 
Medical Monitor (Study Medical Expert) name [CONTACT_3669] [CONTACT_55861] (TMF). 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CONFIDENTIAL Clinical Study  Protocol
No.BAY 2433334 / 1976 6
Version 1.0 Page:  3of 86
Table of Contents
Title Page ................................................................................................................................... 1
Sponsor Signatory .................................................................................................................... 2
Table of Contents ...................................................................................................................... 3
Table of Tables.......................................................................................................................... 6Table of Figures........................................................................................................................ 61.Protocol Summary ............................................................................................................. 7
1.1 Synopsis ........................................................................................................................... 7
1.2 Schema ........................................................................................................................... 10
1.3 Schedule of Activities (SoA) ......................................................................................... 11
2. Introduction ..................................................................................................................... 14
2.1 Study  Rationale .............................................................................................................. 15
2.2 Background .................................................................................................................... 15
2.2.1 Disease Background ................................................................................................... 15
2.2.2 Treatment Guidelines .................................................................................................. 16
2.2.3 FXIa Inhibition: Mode of Action ................................................................................ 17
2.2.4 BAY2433334 .............................................................................................................. 17
[IP_ADDRESS] Preclinical / Toxicology  Data .................................................................................. 17
[IP_ADDRESS] Clinical Data............................................................................................................ 18
2.3 Benefit/Risk Assessment ............................................................................................... 19
3.Objectives and Endpoints ............................................................................................... 22
4.Study Design .................................................................................................................... 24
4.1 Overall Design ............................................................................................................... 24
4.1.1 Study  Design: Part A and Part B ................................................................................ 25
4.1.2 MRI  Procedures .......................................................................................................... 25
4.2 Scientific Rationale for Study  Design ............................................................................ 26
4.3 Justification for Dose ..................................................................................................... 27
4.4 End of Study  Definition ................................................................................................. 28
5.Study Population ............................................................................................................. 28
5.1 Inclusion Criteria ........................................................................................................... 28
5.2 Exclusion Criteria .......................................................................................................... 29
5.3 Lifesty le Considerations ................................................................................................ 31
5.4 Screen Failures ............................................................................................................... 31
6.Study Intervention ........................................................................................................... 31
6.1 Study  Interventions Administered ................................................................................. 31
6.2 Preparation / Handling / Storage / Accountabilit y......................................................... 32
6.3 Measures to Minimize Bias: Randomization and Blinding ........................................... [ADDRESS_60951] Surgery  or 
Percutaneous/Endoscopic Procedures ........................................................................ 35
CONFIDENTIAL Clinical Study  Protocol
No.BAY 2433334 / 1976 6
Version 1.0 Page:  4of 86
6.5.4 Guidance for Management of Participants who Experience Recurrent Ischemic 
Stroke .......................................................................................................................... 36
6.5.5 Guidance for Management of Participants who Experience new M yocardial 
Infarction During the Study ........................................................................................ 36
6.6 Dose Modification ......................................................................................................... 37
6.7 Intervention after the End of the Study .......................................................................... 37
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .......................................................................................... 37
7.1 Discontinuation of Study I ntervention ........................................................................... 37
7.1.1 Temporary  Discontinuation ........................................................................................ 39
7.2 Participant Discontinuation/Withdrawal from the Study ............................................... [ADDRESS_60952] to Follow Up .......................................................................................................... 39
8.Study Assessments and Procedures ............................................................................... 40
8.1 Efficacy  Assessments ..................................................................................................... 40
8.1.1 Primary  efficacy  endpoint ........................................................................................... 40
[IP_ADDRESS] Stroke ....................................................................................................................... 41
8.1.2 Secondary  efficacy  endpoints ..................................................................................... 41
[IP_ADDRESS] Systemic Embolism ................................................................................................. 42
[IP_ADDRESS] Myocardial Infarction .............................................................................................. 42
[IP_ADDRESS] Cardiovascular Death .............................................................................................. 42
8.2 Safety  Assessments ........................................................................................................ 42
8.2.1 Primary  safet y endpoint .............................................................................................. 42
[IP_ADDRESS] ISTH Major Bleeding .............................................................................................. 42
[IP_ADDRESS] ISTH Clinicall y Relevant Non- Major Bleeding ...................................................... 43
8.2.2 Secondary  safet y endpoints ........................................................................................ 43
[IP_ADDRESS] ISTH Minor bleeding .............................................................................................. 43
8.2.3 Exploratory  safety  endpoint ........................................................................................ 43
[IP_ADDRESS] TIMI Bleeding Definitions ...................................................................................... 43
[IP_ADDRESS] BARC Bleeding Definition ..................................................................................... [ADDRESS_60953] ............................................................................... 48
8.4 Treatment of Overdose ................................................................................................... 48
8.5 Pharmacokinetics ........................................................................................................... 49
8.6 Pharmacod ynamics ........................................................................................................ 49
8.7 Genetics .......................................................................................................................... 50
8.8 Biomarkers ..................................................................................................................... 50
8.9 Immunogenicity Assessments ........................................................................................ 51
8.10 Health Economics / Medical Resource Utilization and Health Economics ................... 51
CONFIDENTIAL Clinical Study  Protocol
No.BAY 2433334 / 1976 6
Version 1.0 Page:  5of 86
9. Statistical Considerations ............................................................................................... 51
9.1 Statistical Hy potheses .................................................................................................... 51
9.2 Sample Size Determination ............................................................................................ 51
9.3 Populations for Analy ses............................................................................................... 52
9.4 Statistical Analy ses........................................................................................................ 52
9.4.1 General Considerations ............................................................................................... 52
9.4.2 Primary  Endpoints ...................................................................................................... 53
9.4.3 Secondary  Endpoints .................................................................................................. 55
9.4.4 Tertiary /exploratory  Analy ses.................................................................................... 56
9.4.5 Other Safet y Anal yses................................................................................................ 56
9.4.6 Other Anal yses............................................................................................................ 56
9.5 Interim Anal yses............................................................................................................ 56
9.6 Independent Data Monitoring Committee (IDMC) ....................................................... 57
10. Supporting Documentation and Operational Considerations .................................... 5810.1 Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ........................ 58
10.1.1 Regulatory  and Ethi cal Considerations ...................................................................... 58
10.1.2 Financial Disclosure ................................................................................................... 58
10.1.3 Informed Consent Process .......................................................................................... 58
10.1.4 Data Protection ........................................................................................................... 59
10.1.5 Committees Structure ................................................................................................. 59
[IP_ADDRESS] Executive Committee .............................................................................................. 59
[IP_ADDRESS] Steering Committee (SC) ........................................................................................ 59
[IP_ADDRESS] IDMC ....................................................................................................................... 60
[IP_ADDRESS] Clinical Events Committee (CEC) .......................................................................... 60
10.1.6 Dissemination of Clinical Study  Data ........................................................................ 60
10.1.7 Data Qualit y Assurance .............................................................................................. 61
[IP_ADDRESS] Data Recording ........................................................................................................ 61
[IP_ADDRESS] M onitoring ............................................................................................................... 62
[IP_ADDRESS] Data processing ....................................................................................................... 63
[IP_ADDRESS] Missing data ............................................................................................................ 63
[IP_ADDRESS] Audit and inspection ................................................................................................ 63
[IP_ADDRESS] Archiving ................................................................................................................. 63
10.1.8 Source Documents ...................................................................................................... 64
10.1.9 Study  and Site Start and Closure ................................................................................ 64
10.1.10 Publication Policy ....................................................................................................... 64
10.2 Appendix 2: Clinical L aboratory  Tests .......................................................................... 65
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting .............................................................................................. 67
10.3.1 Definition of AE ......................................................................................................... 67
10.3.2 Definition of SAE ....................................................................................................... 68
10.3.3 Recording and Follow-Up of AE and/or SAE............................................................ 69
10.3.4 Reporting of SAEs ...................................................................................................... 70
10.3.5 Event Reporting Process Overview ............................................................................ 71
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy  Information ......... 71
10.5 Appendix 5: L iver Safet y: Suggested Actions and Follow -up Assessments ................. 73
10.6 Appendix 6: Calculating the Child -Pugh Score ............................................................. 74
10.7 Appendix 7: Calculating Glomerular Filtration Rate..................................................... 7510.8 Appendix 8: Outcome Events: Data Collection............................................................. 75
CONFIDENTIAL Clinical Study  Protocol
No.BAY 2433334 / 1976 6
Version 1.0 Page:  6of 86
10.9 Appendix 9: Study  MRI procedure ................................................................................ 75
10.10 Appendix 10: Modified Ranking Score ......................................................................... 76
10.11 Appendix 11: NI H Stroke Scale .................................................................................... 76
10.12 Appendix 12: Abbreviations .......................................................................................... 81
11.References ........................................................................................................................ 84
Table of Tables
Table 1–1 PK, PD and Biomarker Sampling ........................................................................... 14
Table 3–1 Objectives and Endpoints ........................................................................................ 22
Table 4–1 BAY 2433334: doses selection for Phase 2 ............................................................ 28
Table 6–1 Study  interventions .................................................................................................. 32
Table 10–1 Protocol -Required Safet y Laboratory  Assessments .............................................. 66
Table 10–2 Liver function monitoring ..................................................................................... 74
Table 10–3 Grading of severit y of liver disease ....................................................................... 74
Table 10–4 Child -Pugh score ................................................................................................... 74
Table of Figur es
Figure 1 –1Study  design overview .......................................................................................... 10
Figure 2 –1 Ischemic stroke sub- type classification (TOAST criteria) ..................................... 16
Figure 2 –[ADDRESS_60954] activation .................................................................................................. 17
CONFIDENTIAL Clinical Study  Protocol
No.BAY 2433334 / 1976 6
Version 1.0 Page:  7of 86
1. Protocol Summary
1.1 Synopsis
Protocol Title: Multicenter, randomized, placebo -controlled, double -blind, parallel 
group, dose -finding Phase 2 study to evaluate efficacy  and safety  of 
BAY 2433334 in patients following an acute non- cardioembolic 
ischemic stroke
Short Title: PACIFIC -STROKE -Phase 2 Program of AntiCoagulation via 
Inhibition of F XIa by [CONTACT_50906] C ompound BAY 2433334 – non-
cardioembolic STROKE study )
Rationale: This study  will assess the dose response of BAY 2433334 in order to 
determine the dose that is efficacious and safe and that can be used in a 
Phase 3 study  in the same indication. Current guidelines recommend 
antiplatelet therap y for patients after a non -cardioembolic isc hemic 
stroke / transient ischemic attack (TIA). The addition of a FXIa 
inhibitor on top of antiplatelet therap y is expected to lead to a benefit 
regarding secondary  prevention of stroke combined with no or only  
minimal increase in bleeding and especiall y no increase in major 
bleeding.
Objectives and Endpoints:
Objectives Endpoints
Primary
to assess the dose response of 3 different 
doses of BAY 2433334 compared to 
placebo in reducing the composite of symptomatic ischemic strokes and covert 
brain infarcts detected by [CONTACT_12705] ( MRI)as well as other 
cerebro -and cardiovascula r endpoints in 
participants with an acute non-cardioembolic ischemic stroke and who are treated with antiplatelet therapy.Primary Efficacy Endpoint
composite of sy mptomatic ischemic stroke 
and covert brain infarcts detected by [CONTACT_55862]
composite of sy mptomatic ischemic stroke 
and covert brain infarcts detected by [CONTACT_9268], CV death, m yocardial infarction and s ystemic 
embolism
symptomatic ischemic stroke
covert brain infarcts detected by [CONTACT_9268]
symptomatic ischemic stroke, CV death, 
myocardial infarction 
symptomatic ischemic and hemorrhagic 
stroke 
disabling stroke (mRS ≥4)
all-cause mortality
to evaluate whether the incidence of 
bleeding for BAY 2433334 is similar 
compared to placebo in participants with an 
acute non -cardioembolic ischemic stroke 
and who are treated withantiplatelet 
therapy .Primary Safety Endpoint
composite of International S ociety on 
Thrombosis and Hemostasis (ISTH) major bleeding and clinically relevant non -major 
(CRNM) bleeding
Secondary Safety Endpoints
all bleeding
ISTH major bleeding
ISTH CRNM bleeding
ISTH minor bleeding
Intracerebral hemorrhage (non- traumatic)
CONFIDENTIAL Clinical Study  Protocol
No.BAY 2433334 / 1976 6
Version 1.0 Page:  8of [ADDRESS_60955] ratio of the composite of International Society  on 
Thrombosis and Hemostasis (ISTH) major bleeding and clinicall y relev ant non -major 
(CRNM) bleeding comparing pooled BAY [ADDRESS_60956] one dose of study  medication of BAY 2433334 or placebo and while the 
participant is alive and exposed to study  drug.
The secondary  efficacy  estimand for the following endpoints:
composite of sy mptomatic ischemic stroke and covert brain infarcts detected by  [CONTACT_9268], 
CV death, my ocardial infarction and s ystemic emb olism
covert brain infarcts detected b y MRI 
is the incidence in 6months of each of the individual endpoints following a non -
cardioembolic ischemic stroke in adult participants treated with antiplatelet therap y, while 
alive and regardless of treatment discontinuation, for each of the different doses of BAY 
2433334 and placebo.
The secondary  efficacy  estimand for the following endpoints:
symptomatic ischemic stroke
symptomatic ischemic stroke, CV death, m yocardial infarction 
symptomatic ischemic and hemorr hagic stroke
disabling stroke (mRS ≥4)
all-cause mortality
is the hazard ratio of each of the individual endpoints following a non -cardioembolic ischemic 
stroke in adult participants treated with antiplatelet therap y,while alive and regardless of 
treatment discontinuation, comparing each of the different doses of BAY 2433334 with 
placebo. Details are described in Section 9.4.3.
The secondary  safet y estimand is similar to the primary  safet y estimand for the following 
endpoints:
all bleeding
ISTH major bleeding
ISTH CRNM bleeding
ISTH minor bleeding
Intracerebral hemorrhage (non -traumatic)
Details are described in Section 9.4.3.
Overall Design:
Study  [ZIP_CODE] is a multicenter, randomized, placebo controlled, double -blind, parallel group, 
dose-finding study .
CONFIDENTIAL Clinical Study  Protocol
No.BAY 2433334 / 1976 6
Version 1.0 Page:  9of [ADDRESS_60957] of 2 parts, Part A (minor strokes) and Part B (minor and moderate 
strokes). The initiation of Part B will be based on an interim anal ysis.
Stratification will be based on whether participants will receive single or dual antiplatelet 
therap y after the index stroke and randomization.
If all information is available, participants can be randomized on the day  of screening.
Disclosure Statement: This is a parallel group treatment study  with 4 arms that is participant 
and investigator blinded. 
Intervention Model: Parallel
Primary Purpose: TreatmentNumber of Arms: 4 arms (3 investigational drug arms and 1 placebo arm)
Number of Participants:
Approximately  1900 patients will be screened to achieve 1800 randomized participants for an 
estimated total of 450 evaluable participants per intervention group. More details are available 
in Section 9.2.
Intervention Groups and Duration:
BAY 2433334 is the sponsor’s study  drug under investigation. Placebo is used as comparator. 
Study intervention duration and dose regimen ar e tabulated as follows:
Study Period Duration* Dose and Frequency Route of
administration
Screening Within 48 hours of the 
onset of sy mptoms of 
ischemic stroke BAY 2433334 10 mg once daily
BAY 2433334 20 mg once daily
BAY 2433334 50 mg once daily
Placebo once daily OralIntervention 26-52 weeks* 
Safety Follow -up 2 weeks
Total planned 
number of 
participantsTotal planned study duration
1800 Between 28 and 54 weeks
*The Study Treatment End Date will be [ADDRESS_60958] participant is randomized in the 
study, the maximum treatment duration beyond this date will be no longer than an additional 26 weeks. Thus, participants will hav e a total treatment duration of a minimum 26 weeks to a 
maximum of 52 weeks.
Data Monitoring Committee: Yes
CONFIDENTIAL Clinical Study  Protocol
No.BAY 2433334 / 1976 6
Version 1.0 Page:  10of 86
1.2 Schema
Figure 1–1 Study design overview
Abbreviations:
EOT = End of Treatment; IA = Interim Analysis; MRI = Magnetic Resonance Imaging ; OD = Once 
Daily; RND = Randomization , N = total number of participants, W  = Week

CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / 1976 6
Version 1.0 Page:  11of 86
1.3 Schedule of Activities (SoA)
Study  periods
(Duration)Screening
(SCR)aIntervention period Safety  
Follow -up (SFU)
(14 days after EO T or 
ET)(from RND until End of Treatment visit [EOT],26 to 52 weeks)Early 
termina tion 
(ET)b
Visit number 1 2 3 4g5 6 7 8 9 10 11 12 12a 13
Visit ty pe site site  site  site  site  site  site Site (site)
Week [W]
Study day and allowed 
deviationsSCR
-2 1RND/W0
1W2
15±4W4
29±4W8
57±4W13
92±4W20
141±4W26
183± 4W32
225± 4W39
274± 4W46
323± 4W52/EO T
365±4 Any time
ET+7EOT or ETc +2 weeks
379+[ADDRESS_60959] X
Inclusion and exclusion 
criteriaX Xd
Demographics and 
biometricsX
Medical history X
Prior and Concomitant 
medicationX XdXeX XeX XeX XeX XeX X X
Clinical procedures  / assessments
mRSf, NIHSS assessment X XdXfX X X
12-lead ECGgXcXdX X X
Vital signs (BP and HR) X XdX X X X X X
Adverse  events =========================== ========= continuously ============ =========================== 
Outcome eventsh================== ================== continuously ============ =========================== 
bMRIi[Part Aand/or B] 
(study day and 
allowed time window)A,B
 (-2+3)Aj 
(±7)A,B 
(±7)A,B
 (+7)
IxRS
Randomization /Visit 
registration via IxRSX X X X X X X
Laboratory  assessments
Safety blood sample XkXd,kX X X X X X
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / 1976 6
Version 1.0 Page:  12of 86
Abbreviations: BP = blood pressure, CRF = case report form, ECG = electrocardiogram, eGFR =estimated glomerular filtration rate, EoT = end of treatment, ET = early 
termination, HR =heart rate, IxRS =Interactive Voice/ Web Response System, MRI = magnetic resonance imaging, mRS = modified ranking score, NIHSS = National 
Institute of Health Stroke Scale, PD=pharmacodynamic(s), PK =pharmacokinetic(s), RND = randomization, SCR = screening, SFU =safety follow -up, SoA =Schedule of 
Activities, TIA= transient ischemic attack, W = week
a Screening, randomization and intake of first study drug must occur within 48 hours ofsymptom onset.
bThe visit can be performed at a later time point if participant on inpatient rehabilitation facility and this visit cannot be arranged.
c Participants will perform their safety follow -up phone call 2 weeks after the E OT visit or the ET visit whichever occurs earlier. (i.e. in case of Early Termination 
[ADDRESS_60960] study drug intake).
dIn case screening and randomization are performed on the same day, this procedure does not need to be repeated.
e At Visit 3, 5, 7, 9 and 11: any new concomitant medication and AEs or outcome event will be captured during the calls.
fmodified Ranking Score (mRS) (Section 10.10 ) and NIH SS (Section 10.11 ) should be assess edas follows : 
Index event: at time of screening and time of randomization (NIHSS), day 7 after the event (or at hospi[INVESTIGATOR_2345], if this occurs before day 7; NIHSS 
and mR S), at 3, 6 and 12 months visits (mRS). 
For recurrent stroke events: maximum score during hospi[INVESTIGATOR_059] (NIHSS) ,day 7 after the event (or at hospi[INVESTIGATOR_2345], if this occurs before day 7: 
NIHSS and mRS); visit closest to 3 months after recurrent stroke (mRS) .
gECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QTc intervals should be used.Study  periods
(Duration)Screening
(SCR)*Intervention period Safety  
Follow -up (SFU)
(14 days after EOT or 
ET)(from RND until End of Treatment visit [ EOT], 26 to 52 weeks)Early 
termination 
(ET)b
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 12a 13
Visit type site site  site  site  site  site  site Site (site)
Week [W]
Study day and allowed 
deviationsSCR
-2 1RND/W0
1W2
15±4W4
29±4W8
57±4W13
92±4W20
141±4W26
183±4W32
225±4W39
274±4W46
323±4W52/EOT
365±4 Any time
ET+7EOT or ETc +2 weeks
379+7
Pharm acokinetic samplelX X X
Pharm acodynamic samplinglX X X X
Pharm acogenetic sample X
Biomarker samplinglX X X
Study  drugmadministration
Study drugmdispensation XnXnXnXn
Study drugmintake at the 
sitel X X X no intake
Stud drugmcollection and 
accountabilityX X X X X
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / 1976 6
Version 1.0 Page:  13of 86
houtcome events including all bleeding, death, MI ,recurrent stroke and s ystemic embolism as well as events indicative of a potential outcome (Section 
[IP_ADDRESS] ) need to be reported on dedicated forms in the eCRF on an ongoing basis, even if the participant is permanently discontinued from study treatment.
i MRI is required before or latest within [ADDRESS_60961] and ALT values measured in the local laboratory for screening .Current local laborator y results available for the index 
hospi[INVESTIGATOR_55831] .Full safety la boratory assessments to be done at randomization in the c entral laboratory .
l Refer to Table 1–1PK, PD and Biomarker sampling.
m“Study drug ”refers to “study intervention’ as defined in Section 6.1.
nAt each contact, participants should be again instructed regarding study drug compliance .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  14of 86
PK, PD and Biomark ers Sampling
An overview of the PK, PD and Biomarkers sampling is shown in Table 1–1.
Table 1–1PK, PD and Biomarker Sampling
Day 1
(Visit 2)Week 4 
(Visit 4a)Week 4 or later
(Visit 4 
or subsequent 
visit)Week 26 
(Visit 8) /
ETd
Predose 
Day 1Predose0.5-1.5h 
Postdose2-4 hb
Postdose4-12 hb,c
postdosePredose
PKeX x X x x
PDex X x X x x
Biomarke
rs Plasma x x
Biomarke
rs Serum x x
Genetics x
Abbreviations: ET =Early  termination, PD=pharmacodynamic(s), PK =Pharmacokinetic(s)
aAt Visit 4: in order to collect pre -dose samples for PK and PD, participants should take their study 
drug at the site only after blood sampling. The investigator must record the time when the study 
drug is taken at the site. A phone call to remind the participants is recommended .
b The minimum time between the 2- [ADDRESS_60962]-dose can be taken at week 4 (visit 4) or at a later -on visit (e.g. Visit 6) . 
The exact time of when the study drug was administered must be recorded as well as PK and PD 
post-dose sample collection time.
dAt Visit 8 (week 26 ) in order to collect pre -dose sam ples for PK and PD, participants should take 
their study  drug at the site only after blood sampling. The investigator must record the time when 
the study drug is taken at the site. A phone call to remind the participants is recommended .
However, in case Vi sit 8 is also the EOT visit as well as i n case the sample is taken at ET visit, no 
study drug will be administered.
eIf study drug istemporarily stopped, PK / PD blood samples should only be obtained if study drug has
been restarted and sustained for at least [ADDRESS_60963] recent study drug intake (i.e: on the PK / PD sampling day, as well as the day before that ).
2. Introduction
BAY [ADDRESS_60964], potent inhibitor of activated coagulation factor XI (FXIa) being 
developed for three main indications:
1.Prevention of stroke and sy stemic embolism in patients with AF (cardioembolic stroke 
prevention) 
2.Secondary  stroke prevention in patients after an ischemic stroke (large artery , lacunar 
stroke, or embolic stroke of undetermined source [ESUS]) (non-cardioembolic stroke 
prevention)
3. Prevention of major adverse cardiac events (CV death, MI, stroke) in patients after an 
acute m yocardial infarction (AMI) 
Study  [ADDRESS_60965] placebo in par ticipant s following an acute non -cardioembolic ischemic 
stroke who are planned to be treated with antiplatelet therap y at the discretion of the 
investigator . 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  15of 86
The current clinical development of BAY 2433334 (FXIa inhibitor) in cludes two additional 
Phase 2 studies in par ticipant s with AF (stud y [ZIP_CODE]) and in pa rticipant s with AMI (study  
[ZIP_CODE]). These two studies are planned to have a treatment duration of [ADDRESS_60966] api[INVESTIGATOR_3822] (NOAC) and BAY [ADDRESS_60967] placebo, added on top of 
antiplatelet therap y. This approach is supported b y data from the COMPASS study  in patients 
with stable coronary  and peripheral artery  disease. Patients who received the combination of 
2.5 mg bid rivaroxaban plus ASA had fewer ischemic/uncertain stroke when compared to 
those who received ASA alone (HR 0.5 8) (Sharma et al. 2019 ).
Inhibition of FXIa is expected to lead to a benefit versus placebo regarding secondary  
preven tion of ischemic stroke as well as to not lead to a relevant increase in bleeding and 
especiall y major bleeding. This is based on the available preclinical data, data from patients 
with inherited FXI deficiency  and first clinical data from 2 Phase 2 proof -of-concept studies 
in patients undergoing total knee replacement (please see Section 2.3). 
The primary  endpoint will be sy mptomatic ischemic stroke and covert brain infarcts . Cover t
brain infarcts are also called silent strokes and are identified by  [CONTACT_9268] . These are seen in 30% 
of the elderl y and are 2 -4 times more frequent  compared with symptomatic strokes. Covert
brain infarcts occur in regions of the brain that do not lead to ty pi[INVESTIGATOR_55832] (i.e. 
hemiparesis) and hence clinical diagnosis , but they are linked to vascular cognitive 
impairment gait disorders, depression and dementia. I n addition, available data indicate that 
covert brain infarcts are similarly reduced as symptomatic strokes by[CONTACT_55863] a history  of CAD or PAD
based on COMPASS study (Sharma M et al. 2019 )BAY [ADDRESS_60968] ever stroke in 2016 and 5.5 million peop le 
died of a stroke (Johnson et al. 2019). About 25% of all ischemic strokes are re current strokes.  
The ischemic stroke recurrence rate is substantial and remains at 3 to 6% per year despi[INVESTIGATOR_55833] -recommended preventive therapi[INVESTIGATOR_014] .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  16of 86
Non-cardioembolic stroke includes lacunar stroke, large artery arteriosclerotic stroke and 
cryptogenic stroke  / ESUS, that together account for 75% of all ischemic strokes and are 
currentl y treated with antiplatelet therap y (e.g. A SA, clopi[INVESTIGATOR_7745], A SA+ dipyridamole). 
Figure 2–1 I schemic stroke sub-type classification (TOA ST criteria)
Source: adapted from (Adams et al. 1993 , Hart et al. 2014 ); 
TOAST =Trial of ORG [ADDRESS_60969] of care according to 
current guidelines (2008 European Stroke Organization guideline ( Ringleb et al. 2008 ), the 
2014 American Heart Association revised guideline for the prevention of stroke (Kernan et al. 
2014), 2018 guidelines for the early  management of patients with acute ischemic stroke
(Powers et al. 2018 ), the [ADDRESS_60970] Physicians guideline (Lansberg et 
al. 2012) , and the [ADDRESS_60971] Practice Recommendations for Stroke Care (Coutts et 
al. 2015) . Preferences for standard of care antiplatelet therap y varies by [CONTACT_55864] , stroke management guidelines recommend a range of single antiplatelet therap ies 
thatinclud eacetylsalicy lic aci d (ASA), clopi[INVESTIGATOR_7745], the combination of ASA and 
dipyridamole or ASA and cilostazol. Recent studies ( Johnston et al. 2018, Wang et al. 2013 )
support the use of dual antiplatelet therap y  with ASA and clopi[INVESTIGATOR_55834] 21 day s after an 
acute ischemic stroke ,and although widely used in Europe and North America , this 
combination has not as yet been consistentl y advocated in stroke management guidelines
(Johnston et al. 2016, Johnston et al. 2018, Wang et al. 2013 ).
The use of anticoagulation therap y in patients with non -cardioembolic ischemic stroke is 
currentl y not recommended. In contrast, in patients with atrial fibrillation (AF) suffering a 
stroke or TIA, anticoagulation is recommended, but initiation of NOACs is typi[INVESTIGATOR_1306] y delay ed 

CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  17of 86
for1-3-6-12 day s after the stroke or TIA depending on the s everit y (TIA -minor -moderate -
severe stroke).   
2.2.3 FXIa Inhibition :Mode of A ction
BAY [ADDRESS_60972], potent inhibitor of activated coagulation factor XI (FXIa). 
The plasma serine protease zy mogen factor XI (FXI) is activated after initiation of the con tact 
activation pathway  via factor XIIa (FXIIa) and during the amplification phase as part of a 
positive feedback loop through activation b y thrombin (Figure 2–2). FXIa is thought to 
contribute strongl y to clot progression, which may potentially  lead to vessel occlusion and 
pathological manifestations of thrombosis, but has minor impact on hemostasis due to its 
limited role in the initiation phase of the extrinsic pathwa y. 
FXIa inhibition by  [CONTACT_55865] 2433334 may  offer the opportunity  to prevent thrombosis without 
interference with primary hemostasis and to thereby  [CONTACT_55866] a paradigm shift compared to Vitamin 
K antagonists and Non -Vitamin K oral anticoagulants (NOACs).
Figure 2–2Contact [CONTACT_55867]: adapted from Chen et al. 2014 ( Chen et al. 2014 ).
2.2.4 BAY2433334
[IP_ADDRESS] Preclinical / Toxicology Data
Preclinical data using FXI -deficient mice or studies using pharmacological inhibition of FXIa 
in different animal models, for example a FeCl- induced thrombosis model, showed a benefit 
in reduced thrombus formation. The data indicate that higher efficacy  might be possible to 
achieve when compared to the therapeutic doses of NOACs. 
The benefit in these animal models was combined without an associated increase in bleeding 
time as is seen for NOACs in these models. Importantly , no further increase in bleeding time 
was seen even when BAY2433334 was given on top of dual antiplatelet therap y.
Data regarding toxicology  studies as well as more preclinical data can be found in the 
Investigator`s Brochure but are also partly  described in the benefit/risk section (seeSection 
2.3). 

CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  18of 86
[IP_ADDRESS] Clinical Data
So far, [ADDRESS_60973] received treatment with BAY 2433334 in doses 
ranging from 5 mg to 150 mg after single dosing and u p to 100 mg once daily  in multiple dose 
settings. 
Safety
The single dose escalation study  (study  [ZIP_CODE]) with BAY [ADDRESS_60974] study  part 
with 25 mg. No cli nically  relevant signs or s ymptoms of bleeding were observed.
The multiple dose escalation study  (study  [ZIP_CODE]) has also been clinically  completed and the 
evaluation is still ongoing. Therefore, the results are preliminary . It consisted of three parts: 
Part A, where 25 mg, 50 mg and 100 mg BAY 2433334 were given once daily  over 9 
consecutive days, P art B, where 25 mg were given twice dail y, and Part C, where a 
midazolam interaction was investigated with 25 mg and 75 mg BAY 2433334. 
Overall, BAY 2433334 was safe and well tolerated. More details on safety  can be found in the 
Investigator ’s Brochure.   
Pharmacodynamics 
The following pharmacody namic parameters were investigated in both the FiM study  (study  
[ZIP_CODE]) and MDE stud y (study  [ZIP_CODE]): aPTT, FXI activity  (AXIA assay ), and FXI 
concentration. Bleeding time was investigated after single dose administration only  (study  
[ZIP_CODE]).
A dose dependent prolongation of aPTT was observed after single dosing with a close direct 
correlation between aPTT and plasma concentration: 
In the 25 mg OD dose step of the multiple dose ( MD)study  [ZIP_CODE] a prolongation of 
aPTT of  (mean, compared to baseline) after single dosing a nd  (mean) at 
steady  state was seen. 
In the 50 mg OD dose step of the MD study [ZIP_CODE] a prolongation of aPTT of  
(mean, compared to baseline) after single dosing and  (mean) at steady  state 
was seen. 
In the 100 mg OD dose step of the MD stud y19665 a prolongation of aPTT of  
(mean, compared to baseline) after single dosing and  (mean) at steady  state 
was seen. 
FXI activity  (AXIA assay ) is inhibited by  a mean of ~85% after 25  mg single dose ( SD)and a 
mean of ~95% (25  mg OD) at stead ystate. After 50 mg and 100 mg SD and MD, activated 
FXI activity  is inhibited by  a mean of >95% both after first dose and at steady  state. The 
duration of the inhibition of FXI activity  (AXIA assay ) is dose dependent. Complete 
inhibition was reported for 1 2 hours for 50 mg at steady state and this is prolonged up to 24 
hours for 100 mg at steady state.
Pharmacod ynamic parameters aPTT and FXI activity  correlated well with observed plasma 
concentrations of BAY 2433334.No relevant changes of FXI concentration or PT were observed in either study . 
No clinically  relevant changes in bleeding time were observed after single dose application. 
Pharmacokinetics
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  19of 86
The key  pharmacokinetics features of BAY 2433334 based on current available data and 
when administered as IR tablets can be summarized as follows. 
BAY 2433334 is absorbed with a median time to reach maximum plasma 
concentration (t max) of 2 to 4 hours (fasted state).
There is no hint for an y deviation from dose -proportionality  found for doses between 
5mg and 150mg.
Relative bioavailability  of BAY 2433334 administered as I R tablet amounted to 
approximately  89.5% with regard to AUC and of 86.0% with regard to C max, compared 
as oral solution
A high -fat, high -calorie meal has minor effect on the AUC of 25 mg BAY 2433334 
(decrease of 12.4%) and results in a reduced absorption rate (31.4% decrease in 
maximum plasma concentration [C max] and 2.5 h prolongation in t max).
The variabilit y was low to moderate for AUC and C max(%geoCV approx. 15 to 30%).
The degree of accu mulation of BAY 2433334 is low regarding C max,md or AUC τ,md
after once daily multiple dosing with R ACmaxbetween 1.4 and 1.6 and R AAUC 
between 1.5 and 1.7.
Pharmacokinetics were linear over time. 
The metabolite M -10 (BAY 2826102, formed b y amide hy droly sis of the central 
amide and subsequent N-acetylation) is expected to be a main compound in human 
plasma with a metabolic ratio to parent drug of approx. 24 to 37% . This metabolite is 
not pharmacolog ically active.
Terminal half -life is 14.5 to 16.0 hours supporting once dail y dosing.
Low apparent oral plasma clearance (CL/F) of about 3.19-4.27 L/h was observed in 
geometric mean (corresponding to a blood clearance/F of 4.54 -6.07 L/h).
Based on prelimin ary evaluation of the 50 mg dose step in the multiple dose escalation 
study  (study  [ZIP_CODE]) renal elimination was low ( <15%).  
Based on the preliminary ethnic evaluation up to the 50 mg dose step of single and 
multiple dose in Caucasians (study [ZIP_CODE]) and J apanese (stud y [ZIP_CODE]), there is no 
large difference in PK between races though geometric mean of AUC and C maxin 
Japanese were slightly higher than in Caucasians. 
Based on preliminary  evaluation the strong CYP3A4 inhibitor itraconazole increased 
BAY 2433334 exposure by  100% (2- fold) while maximum plasma concentrations 
were not changed (study  [ZIP_CODE]). Terminal half- life was prolonged from 16 to 29 
hours.
More details can be found in the I nvestigator’s Brochure.
2.3 Benefit/Risk Assessment
The FXIa inhibitor BAY [ADDRESS_60975] study  investigating BAY 2433334 in patients after an acute 
non-cardioembolic ischemic stroke. Once daily  doses of 10 mg, 20 mg and 50 mg will be 
tested in the study .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  20of [ADDRESS_60976] to other oral anticoagulants (VKAs and 
NOACs) is not expected to increase the risk for clinicall y significant bleeding, while leading 
to an efficacy  benefit.
The expected clinical profile of BAY [ADDRESS_60977]  unaffected, that is 
activated in case of vessel injury . 
At this stage of development there is no clinical ev idence available yet to confirm the efficacy  
benefit of BAY 2433334. However, the data supporting that this compound is expected to lead to prevention of thrombosis events in the intended indications are the following: 
FXI-deficient knockout mice are protected from thrombosis. I n addition, in various 
thrombosis models in rabbits, BAY 2433334 demonstrated reduced thrombus weight, and this was seen when given with or without antiplatelets. While therapeutic doses of NOACs lead to a 20- 30% reduction in thromb us formation in the same animal models, 
BAY 2433334 was able to reduce the thrombus formation by  [CONTACT_8622] ~ 90%.
In people with inherited Factor XI deficiency , a rare coagulation deficiency  caused by  
[CONTACT_55868] a loss -of-function factor XI 
molecule, a lower risk for venous thromboembolic events as well as cardiovascular events and especiall y stroke has been reported. 
Increased levels of FXI are reported as a risk factor for venous thromboembolism and 
myocardial ischemia or stroke. Whether there is a causal relationship is unclear.
A first proof of concept targeting FXI as anticoagulant has been shown b y a FX I 
Antisense Oligonucleotide. Reducing FXI levels in patients undergoing total knee arthroplast y (TKA) led t o an improved prevention of postoperative venous 
thromboembolism (VTE), when compared to enoxaparin. Based on modeling 
approaches, the inhibition levels of FXIa activity  in the study  can be achieved with the 
20 mg and 50 mg doses of BAY 2433334 (see also t he Investigator’s Brochure).
Phase [ADDRESS_60978] planned dose of 50 mg to be tested in Phase 2 lead to 
inhibition of FXI  activity by  a mean of >  95% and complete inhibition during 12 hours
of the day . This was combined with a mean prolongation of aPTT of . 
At this stage of development, the safet y profile has not been established. The following 
information related to safety  as well as potential risks for participant s is available:
1.Bleeding is the main safety  concern related to antithrombotic therapi[INVESTIGATOR_014]. For an 
inhibitor of FXIa a lower bleeding risk is expected. Data supporting this are listed 
below: 
oFXI-deficient knockout mice do not show as bleeding phenot ype. In addition, 
in the thrombosis animal models no increase in bleeding time (gum and ear) was reported. Importantly , no further increase in bleeding time was seen when 
BAY2433334 was given on top of dual antiplatelet. I n addition, in the 
toxicology  studies no relevant bleeding was reported for up to 37- fold the 
expected human exposure of the planned 50 mg multiple dosingin pa rticipants.
oPatients with inherited FXI deficiency  are t ypi[INVESTIGATOR_55835] a prolonged activated partial thromboplastin time (aPTT) in routine 
CCI
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  21of [ADDRESS_60979] a risk for a hemorrhagic transformation of the stroke as well as for 
intracranial bleeding in general. Therefore, in patients with acute ischemic stroke, 
anticoagulants are initiated after a delay  depending on stroke severit y. Based on 
available data a lower risk for bleeding with FXIa inhibition is expected and ther efore, 
early initiation is justified. However, in order to maximize the safety of participants 
Part A will be restricted to patients with a minor stroke. Eligibility  will be expanded to 
include more severe strokes only  after a thorough assessment of bleedi ng events 
during Part A.
2.In toxicology  studies, the liver was identified as a target organ in the rat but not in the 
dog. This included dose-dependent spontaneous, mostly  transient increases in liver 
enzy mes in single animals without clear correlation to histopathological findings in the 
liver. Based on this participants with a >2.[ADDRESS_60980] been safe and well tolerated. This included general safety , 
laboratory , vital signs and ECGs. The doses were 2 and 3 fold higher than planned in 
this Phase 2 study .
4.Based on preliminary  evalu ation the strong CYP3A4 inhibitor itraconazole increased 
BAY 2433334 exposure by  100% (2- fold) while maximum plasma concentrations 
were not changed (study  [ZIP_CODE]). Terminal half- life was prolonged from [ADDRESS_60981] an independent data 
monitoring committee (IDMC) will monitor the safet y of all participants enrolled in all 3 
Phase 2 studies with a focus on bleeding and general safet y.
Several Factor XI (FXI) and activated Factor XI (FXIa) inhib itor assets are currentl y in 
development as antithrombotics, including antisense oligonucleotides (ASOs), antibodies and small molecules (SMOL s).
In summary , in this Phase [ADDRESS_60982] time BAY 2433334. Study  drug will be given on top of SoC
therap y with antiplatelet therap y. The main objective of the study is to explore whether the 
addition of BAY 2433334 will lead to a dose response in reducing s ymptomatic strokes and 
covert brain infarcts and whether this is combined with no relevant increase in bleeding when 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  22of 86
given on top of antiplatelet therap y.An additional objective is to guide dose selection for 
Phase 3. Currentl y, available preclinical and clinical data from the o ngoing study  regarding 
the key  risks do not indicate an unfavorable risk profile for BAY 2433334. The overall risk is 
anticipated to be acceptable in the context of the drug benefit. 
More detailed information about the known and expected benefits and risk s and reasonabl y 
expected adverse events of BAY 2433334 may  be found in the Investigator’s Brochure.
3. Objectives and Endpoints
Objectives and endpoints (primary , secondary  and exploratory ) of the study are reported 
below, in Table 3–1. Please refer to Section 9.4 for further details.
Table 3–1Objectives and Endpoints
Objectives Endpoints
Primary
to assess the dose response of 3 different 
doses of BAY 2433334 compared to 
placebo in reducing the composite of 
symptomatic ischemic strokes and covert 
brain infarcts detected by [CONTACT_55869] -and cardiovascular endpoints 
in participants with an acute non -
cardioembolic ischemic stroke and who a re 
treated with antiplatelet therapy.Primary Efficacy Endpoint
composite of sy mptomatic  ischemic stroke 
and covert brain infarcts detected by [CONTACT_55862]
composite of sy mptomatic ischemic stroke 
and covert brain infarcts detected by [CONTACT_9268], 
CV death, m yocardial infarction and s ystemic 
embolism
symptomatic ischemic stroke
covert brain infarcts detected by [CONTACT_9268]
symptomatic ischemic stroke, CV death, 
myocardial infarction 
symptomatic ischemic and hemorrhagic 
stroke
disabling stroke (mRS≥4)
all-cause mortality
to evaluate whether the incidence of 
bleeding is similar for BAY 2433334 
compared to placebo in participants with an 
acute non -cardioembolic ischemic stroke 
and who are treated withantiplatelet 
therapy .Primary Safety Endpoint
composite of International Society on 
Thrombosis and Hemostasis (ISTH) major bleeding and clinically relevant non -major 
(CRNM) bleeding
Secondary Safety Endpoints
all bleeding
ISTH major bleeding
ISTH CRNM bleeding
ISTH minor bleeding
Intracerebral hemorrhage (non -traumatic)
Exploratory Safety Endpoints
TIMI clinically significant bleeding
TIMI major bleeding
TIMI minor bleeding
BARC bleeding definition Type 2, 3, 5
BARC bleeding definition Type 3, 5
BARC bleeding definition Type 1, 2, 3, 5
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  23of 86
Explora tory
to explore additional pharmacokinetic and 
pharmacodynamic parameters, biomarkers 
and genetics
To further investigate the study intervention 
(i.e. mode -of-action -related effects and / or 
safety ) and to further investigate 
pathomechanisms deemed relevant to 
cardiovascular diseases and associated health problemsOther E xploratory Safety Endpoints
FXIa inhibition, aPTT 
Pharma cokinetics 
Various biomarkers and genetics may be explored (e.g. diagnostic, safety, PD, 
monitoring, or potentially predicti ve 
biomarkers)
Abbreviations: AF =atrial fibrillation, aPTT =activated partial thromboplastin time, BARC =Bleeding 
Academic Research Consortium, CV = cardiovascular, ISTH =International Society on 
Thrombosis and Hemostasis, MI =myocardial infarction, TIMI =thrombolysis in myocardial 
infarction
The p rimary  efficacy  estimand is the incidence of sy mptomatic ischemic stroke or covert 
brain infarcts detected b y MRI  in [ADDRESS_60983] ratio of the composite of International Society  on 
Thrombosis and Hemostasis (ISTH) major bleeding and clinicall y relevant non -major 
(CRNM) bleeding comparing pooled BAY [ADDRESS_60984] one dose of study  medication of BAY 2433334 or placebo and while the 
participant is alive and exposed to study  drug.
The secondary  efficacy  estimand for the following endpoints:
composite of sy mptomatic ischemic stroke and covert brain infarcts detected by  [CONTACT_9268], 
CV death, my ocardial infarction and s ystemic embolism
covert brain infarcts detected b y MRI 
is the incidence in six months of each of the individual endpoints following a no n-
cardioembolic ischemic stroke in adult participants treated with antiplatelet therap y, while 
alive and regardless of treatment discontinuation, for each of the different doses of BAY 
2433334 and placebo.
The secondary  efficacy  estimand for the following endpoints:
symptomatic ischemic stroke
symptomatic ischemic stroke, CV death, m yocardial infarction 
symptomatic ischemic and hemorrhagic stroke
disabling stroke (mRS ≥4)
all-cause mortality
is the hazard ratio of each of the individual endpoints following a non- cardioembolic ischemic 
stroke in adult participants treated with antiplatelet therap y, while alive and regardless of 
treatment discontinuation, comparing each of the different doses of BAY 2433334 with 
placebo. Detail s are described in Sec tion 9.4.3.
The s econdary  safet y estimand is similar to the primary  safet y estimand for the following 
endpoints:
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  24of 86
all bleeding
ISTH major bleeding
ISTH CRNM bleeding
ISTH minor bleeding
Intracerebral hem orrhage (non- traumatic) .
Details aredescribed in Section 9.4.3.
4. Study Design
4.1 Overall Design
Study  [ZIP_CODE] is a multicenter, randomized, placebo- controlled, double -blind, para llel group, 
dose-finding P hase 2 study . The overall study  design is depi[INVESTIGATOR_6517] 1–1.
The study  population includes participants to be randomized within 48 hours of onset of an 
acute non -cardioembolic ischemic stroke who are planned to be treated with antiplatelet 
therap y at th e discretion of the investigator .Approximately  1800 participants (450 per arm) 
will be randomized 1:1:1:1 to 1 of the 3 investigational drug arms (BAY 2433334) or the 
placebo arm, in addition to their standard of care antiplatelet background therap y. 
Thestudy  will consist of 2 parts, Part A (minor stroke s) and Part B (minor and moderate 
strokes) and the following periods:
Screening (Visit 1 until Visit 2) : Within 48 h ours of the onset of s ymptoms
Screening and randomization can take place on the same day if all information 
is available ( Visits 1 and 2 are combined)
Imaging of brain (CT or MRI ) must be available at screening to exclude 
hemorrhagic stroke or other causes of the s ymptoms . 
All participants must have at least one MRI available meeting stud y MRI 
manual specifications either before randomization (as a clinically  initiated 
MRI ) or latest within 72 hours after randomization (asastudy  initiated MRI ).
Participants must be screened, randomized and  study  treatment initiated within 
[ADDRESS_60985] known to be without sy mptoms in case of wake -up stroke.
Stratification will be based on whether participants will receive single or dual 
antiplatelet therap y  after the index stroke and randomization .
Treatment Period (Visit 2 through Visit 12): At least [ADDRESS_60986] a total treatment duration of a minimum 26 weeks to a maximum of 52 weeks.
For details on Part A and B of the treatment phase see S ection 4.1.1.
Safety Follow -up (Visit 13): 14 day s (+ 7 day s) after E OT or ET.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  25of [ADDRESS_60987] at screeni ng and randomization ( Visit 1 and V isit 2), at W eek 4 (Visit 4), at 
Week 13 (V isit 6), Week 26 (V isit 8), Week 39 ( Visit 10) and at W eek 52 / EOT ( Visit 12). 
Telephone calls will take place at Week 2 (Visit 3), Week 8 (Visit 5), Week 20 (V isit 7), 
Week 32 (V isit 9), Week 46 (V isit 11) as well as 2 weeks after the EOT visit for participants 
who will take study  drug until the planned EO T (i.e. safet y follow -up, V isit 13). 
For participants who willprematurel y discontinue from study drug, an earl y terminat ion (ET) 
visit ( Visit 12a) will take place as soon as possible at the study  site. Participants are asked to 
continue the study  schedule of visits until completing all the study visits or end of study  is 
declared. Telephone calls will take place 2 weeks aft er the ET visit (i.e. safety  follow -up, V isit 
13). Further details are described in Section 7.1.
Details of study procedures and their timing are summ arized in the SoA (Section 1.3).
4.1.1 Study Design: Part A and Part B 
Patients after an acute ischemic stroke have an increased risk for intracranial bleeding and 
hemorrhagic transformation of the ischemic stroke area. Patients may also receive 
thromboly sis as acute therapy . Therefore, in patients who had an ischemic stroke and who 
require anticoagulation therap y for example due to AF, anticoagulation is ty pi[INVESTIGATOR_55836] y.
In order to address this safet y concern ( despi[INVESTIGATOR_55837] 2433334) the study  will consist of 2 parts with pa rticipant s with less 
severe strokes to be enrolled in Part A and extended to more severe strokes in Part B if 
warranted b y safet y documented in Part A . In more detail:
Part A will enroll participants with minor stroke only, defined as NIHSS ≤7at time of 
randomization, whereas in 
Part B enrollment will be extended to:
Participants with minor or moderate strokes : NIHSS ≤ 15 at time of randomization
Participants with thromboly sis or endovascular therap y (mechanical thrombectomy ) 
can be randomized >24hr after the intervention; (i.e randomization can take place no 
earlier th an 24 hours after having received these treatments).
The decision to initiate Part B will be taken as part of an interim anal ysis. This will take place
after approximately  50% of participants have been enrolled in the study  or MRI  data (week 
13) is availab le for approximately  12.5% of the participants. Besides data from this study ,also 
data from the concurrently  conducted Phase 2 studies in AFand acute m yocardial infarction 
will be consider ed.For more details on the interim analy sis process, see Section 9.5.
If the interim anal ysis indicates no concern (e.g. no clinically  relevant increase in intracranial 
hemorrhage or hemorrhagic transformation of ischemic stroke) , Part B will be initiated.
In the event that Part B is not  initiated following the interim anal ysis,and there is no safety  
concern that warrants a stop of the study ,enrolment will continue based on Part A eligibility  
criteria until the end of recruitment .
4.1.[ADDRESS_60988] cover tbrain infarcts are based on brain MRI s 
done for routine clinical care ofacute stroke patients. The focus is on the primary  study  
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  26of 86
objective of detecting incident covert brain infarcts. MRI  data will be transmitted to the 
central MRI C ore Laboratory  where MRI interpretation will be done blinded to treatment 
assignment to identify incident brain infarcts, comparing the initial study  MRI  to follow -up 
MRI . Details regarding the procedure , MR I requirements and logistics will be available in a 
MRI  procedure manual. 
The required study  MRI sare to be performed:
either before randomization (as a clinically  initiated MRI ) or within 72 hours after 
randomization (as a study initiated MRI) for all participants (Part A and B) and 
a final study  MRI will be performed for all participants (Part A and B) at W eek 26 
(Visit 8) or ET
astudy  MRI at W eek 13 ( Visit 6) will be performed for Part A participants only  until 
Part B is open. Once Part B is open neither Part A or Part B participants will require 
the MRI  imaging at W eek 13.
In summary , all participants are required to undergo at least two MRI s that meet study  
requirements, and most participants enrolled during Part A will undergo a third MRI  at 
week 13.
Clinical MRI sare acceptable for stud y purposes as long as they comply  with the minimum 
requirements detailed in the MRI  procedure smanual .The MRI requi rement swere designed to 
make it feasible that at most stroke center sthe clinical MRI s done for anacute stroke will 
qualify for use in the study  and not requiring an additional study  MRI . 
If possible, the same MRI machine should be used for all study -related MRIs for an individual 
participant .
Further information is available in Section 10.9 and in a separate MRI procedure smanual.
4.2 Scientific Rationale for Study Design
Study  [ZIP_CODE] is a multicenter, randomized, placebo controlled, double -blind, parallel group, 
dose-finding P hase 2 study in 1800 patients (450 patients per arm) with an acute non-
cardioembolic ischemic stroke. The stud y will apply  the principles of randomization , 
stratification (b y antiplatelet therap y; single vs. dual antiplatelet therap y)and double -blinding 
in order to prevent  bias in the inclusion of patients or reporting of safet y or efficacy events. 
In addition, t he study  will follow a parallel group design in order to prevent bias in the data 
due to e.g. different sites in different countries enrolling at diffe rent timepoints into the study  
or in case of an y seasonally  related differences. There does not appear to be a requirement for 
a dose escalation approach, because based on the available preclinical and clinical data for BAY [ADDRESS_60989] 26 and up to 52 weeks in this Phase 2study in order 
to enable collection of sufficient number of bleeding events as well as efficacy events i.e. 
stroke events, over time . In addition, the longer treatment duration allows to identify  signals 
on delay ed adverse drug reaction. 
Based on our assumptions, 7.5% of participants will experience a symptomatic stroke during 
the study  conduct andin addition twice as many  covert brain infarcts (15%) are expected 
leading to overall 22.5% at 6 months. During the whole study  duration ~ 100 sy mptomatic 
strokes and ~ 200 covert brain infarcts (total ~ 300) are expected to be observed in the study  
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  27of 86
cohort. At the same time, ~ 70 major or CRNM bleeding are expected . This number of events 
is required to provide a signal of efficacy , reassurance about safet y,and allow determination 
of the optimal dose to be selected for Phase 3.
The study  is separated into 2 parts (Part A and Part B). In Part A, only patients with a minor 
stroke will be enrolled, whereas in Part B ,the study  will also be opened up to patients with 
moderate stroke and patients who have undergone thromboly sis or endovascular therap y. This
approach has been chosen to address the increased risk of patients with ischemic stroke for 
hemorrhagic transformation of the ischemic stroke area ,and a generally  higher risk for 
intracranial bleeding. For more details, see section 4.1.1. 
In this study , treatment initiation with BAY [ADDRESS_60990] 7% risk at 48 hours and a 10% risk by  7 day s, even for patients with initial 
mild clinical presentation (Johnston et al. 2016, Johnston et al. 2018 , Wang et al. 2013 ). Earl y 
initiatio n is regarded as acceptable, because the oral FXIa inhibitor BAY [ADDRESS_60991] of care with background antiplatelet therap y. 
The decision on type of antiplatelet therap y will be left to the discretion of the treating 
physician, as there is variance in the current clinical practice . Mandating a single antiplatelet 
regimen might not be widely  acceptable according to local practices or regional guid elines, 
but also not scient ifically required , as the primary  comparison will be BAY 2433334 versus 
placebo.The current clinical development of BAY 2433334 is conducted with three P hase 2studies in 
parallel . Apart from participants with non- cardioembolic ischemic stroke , other studies are 
being conducted in patients with AF as well as acute myocardial infarction (AMI).A common 
Independent Data Monitoring Committee (IDMC) will keep oversight of each one of the 
studies individually  and as overall for Phase 2 studies of BAY 2433334.
The aim of these individual Phase 2 studies is to gain knowledge of the bleeding profile. It is 
not planned to perform hypotheses testing. However, this study ([ZIP_CODE]) is powered to detect a 
dose-response relationship for the primary  efficacy  outcome. Pooled data across the studies
should will add precision concerning safet y in terms of bleeding and general safet y. For this 
purpose, data will be pooled within and across studies.
4.[ADDRESS_60992] the once dail y doses of 10mg (low d ose), 20mg (mid dose) and 50mg 
(high dose) BAY 2433334. 
The selection of the high dose in this study  was not limited by  [CONTACT_49750] y and tolerability data 
from toxicology  studies, nor from the results of the human Phase 1 studies conducted in 
healthy  volunteers. Single doses up to 150 mg or multiple doses up to 100 mg for 9 day s were 
tested in the Phase 1studies. Due to these favorable results, the dose selection for the Phase 2 
studies was primarily  based on pharmacody namic assay s (preclinical and Phase 1 studies) 
including aPTT and FXIa activity. Modeling approaches of the available Phase [ADDRESS_60993] range of inhibition of FXIa and lead to 
differe nt degrees of increases in aPTT ( Table 4–1).
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  28of 86
The high dose of 50 mg was chosen to reach significant inhibition of FXIa and to 
achieve maximum efficacy . However this dose should not lead to a complete 
inhibition of FXIa during the major ity of the day . The selected 50 mg dose is expected 
to lead to a mean FXIa activity of 7 % with FXIa activity  <10% during 14 hours of the 
day. aPTT is predicted to increase to  at trough and  at peak. 
The mid dose of [ADDRESS_60994] a dose linear 
response related to FXIa inhibition. This dose leads to a mean FXIa activity of 23% .
10 mg was selected as the low dose , as lower doses lead to no or only  minimal 
increases in aPTT. For the 10 mg dose, the expected mean FXIa activity  is 45% and 
aPTT is increased to  at trough and  at peak. 
Table 4–1BAY 2433334: dose sselection for Phase 2
Humans, multiple dose, 
modelled
OD dosingPredicted FXIa activity Predicted aPTT increase
Trough % Peak % Mean % Trough % Peak %
50 mg 13 3 7
20 mg 40 11 23
10 mg 67 27 45
Abbreviations: aPTT =activated partial thromboplastin time, OD =once a day
4.[ADDRESS_60995] completed the study  if he/she has completed all phases of 
the study  including the last scheduled study  visit .
The end of the stud y is defined as the date of the last visit of the last participant in the study  
globall y.
5. Study Population
The study  will enroll adult participants within 48 hours of the onset of s ymptoms of an acute 
non-cardioembolic ischemic stroke (index event) documented to be not hemorrhagic by 
[CONTACT_55870] . 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known 
as protocol waivers or exemptions, is not permitted.
5.[ADDRESS_60996] y:
Age
1.Participant must be 45 years of age and older at the time of signing the informed 
consent
Type of Participant and Disease Characteristics
2.Non-cardioembolic ischemic stroke with
a.persistent signs and s ymptoms of stroke lasting for ≥ 24hours OR
b.acute brain infarction documented b y computed tomograph y (CT) or MRI
AND
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  29of 86
c.with the intention to be treated with antiplatelet therap y during the stud y 
conduct1
3.Imaging of brain (CT or MRI ) ruling out hemorrhagic stroke or another pathology  
that could explain sy mptoms (e.g. brain tumor, abscess, vascular malformation)
4.Severity  of index event nearest the time of randomization :
a.Part A :  minor stroke (define d as NIHSS ≤ 7)  can be enrolled
b.Part B : participants with  minor or moderate stroke andNIHSS ≤ 15can be 
enrolled. Participants undergoing thromboly sis or endovascular therap y 
(mechanical thrombectomy ) can be enrolled but at the earliest 24 hours after 
the intervention 
5.Randomization within 48 hours after the onset of symptoms of the index event (or 
after patients were last known to be without sy mptoms in case of wake -up stroke)
6.Ability  to conduct an MRI  either before randomization or within 72 hours after 
randomization
Informed Consent
7. Capable of giving signed informed consent as described in Section 10.1.3 which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol. Written informed consent has to be signed 
before an y stud y procedure .
5.[ADDRESS_60997] y:
Medical Conditions
1.Prior ischemic stroke within last 30 day s of index event 
2.History  of atrial fibrillation* or suspi[INVESTIGATOR_55838] (*12 -lead 
ECG or documented during cardiac rhy thm monitoring)
3.Dysphagia with i nability to safel y swallow stud y medication at time of randomization
4.Contraindication to perform brain MRI (e.g. certain ty pes of aneury sm clips, 
claustrophobia, patients that cannot lie supi[INVESTIGATOR_2525] 30 minutes, patients whose body  
structure exceeds the restrictions of the local MRI instrument ) 
5.Part A only: thromboly sis or endovascular therapy  (mechanical thrombectomy )
                     performed for index event
6. U ncontrolled h ypertension ( systolic blood pressure ≥ 160 mmHg or diastolic blood 
pressure ≥ 100 mmHg) at randomization
7.Active bleeding; known bleeding disorder , history  of major bleeding (intracranial, 
retroperitoneal, intraocular) or clinically  significant gastrointestinal bleeding within last 6 
months of randomization
                                                
1any antiplatelet therapy recommended by [CONTACT_55871], single or dual, is 
permitted based on the choice of the treating physician see Section 6.5.1 .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  30of 86
8. Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or 
hepatic insufficiency  classified as Child- Pugh B or C (see Section 10.7) , or AL T or AST 
> 2.5 x the upper limit ,measured between enrollment and randomization 
9.Estimated glomerular filtration rate (eGFR) < 30 mL /min/1.73 m2calculated by 
[CONTACT_55872] (MDRD) (see Section 10.7), determined between 
enrollment and randomization .
10.Major surgery  during last 30 day s or planned major surgery  or intervention within study  
period (e.g. Carotid endarterectomy, CABG)
11.Known allergy , intolerance or hy persensitivity tothe study  intervention (active substance 
or excipi[INVESTIGATOR_840]).
Prior/Concomitant Therapy
12. Planned use or requirement of full dose and long term anticoagulati on therapy during 
study  conduct2
13.Anticipated need for chronic (more than 4 weeks) therap y with NSAIDs
14.Concomitant use of an y of the following therapi[INVESTIGATOR_6523] 14 days (or at least five half -
lives of the active substance whatever is longer) before randomiz ation and first study  
intervention administration (see Section 6.5):
Strong inhibitors of cy tochrome P450 isoenzy me 3A4 (CYP3A4) e.g. human 
immunodeficiency  virus protease inhibitors, sy stemically  used azole -antimy cotic 
agents, clarithrom ycin or telithromy cin
Strong inducers of CYP3A4, e.g. phen ytoin, carbamazepi[INVESTIGATOR_050], phenobarbital, 
rifampi[INVESTIGATOR_55839]. John’s wort.
Other 
15. Known current alcohol and/or illicit drug abuse that may  interfere with the participant’s 
safet y and/or compliance at the discretion of the inve stigator 
16.Women of childbearing potential (women are considered of childbearing potential if they  
are not surgically  sterile or postmenopausal, defined as amenorrhea for > 12 months) . 
Male participants not willing to use condoms when sexually  active with a woman of 
childbearing potential
17. Close affiliation with the investigational site or sponsor; e.g. a close relative of the 
investigator, or a dependent person (e.g. employ ee or student of the investigational site or 
the sponsor)
18.Previous (within 30 day s or 5 half -lives of the investigational drug, whichever is longer) 
or concomitant participation in another clinical study with investigational medicinal 
product(s) or device(s). Registries and observational studies are allowed.
19.Any condition or therapy, which would make the participant unsuitable for the study  (e.g. 
non-compliance) or otherwise vulnerable (e.g. participant in custody  by [CONTACT_55873] a court) or life expectancy  < 6 months.
                                                
2venous thromboembolism prophylaxis with LMWH or unfractionated heparin for short periods of time is 
allow ed.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  31of [ADDRESS_60998] yle (except for the above 
mentioned substance abuse) and / or diet appl y.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet 
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to que ries from regulatory  authorities. Minimal information includes demography , 
screen failure details and eligibility  criteria.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  not 
be rescreened. 
6. Study Intervention
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
6.1 Study Interventions Administered
The following stu dy interventions will be administered in the stud y:
BAY 2433334: sponsor’s study  drug under investigation
Placebo to BAY 2433334
BAY 2433334 is supplied in various strengths as film -coated, immediate -release tablets with 
identical appearance. BAY 2433334 is taken orally  once a day  in the morning, preferabl y 
around the same time each day . The immediate release tablets will be provided as pi[INVESTIGATOR_8745], oval, 
film-coated tablets containing either 5 mg, 15 mg or 25 mg of BAY 2433334 ( Table 6–1) .
The study  interventions (tablets) are not to be broken, halved or crushed, and should be 
swallowed whole with a glass of water in the morning . Participants will have to take two 
tablets fr om two different bottles (one table t from each bottle) for one dose. Study  drug 
(tablets) can be taken irrespective of food intake.Matching placebos for BAY [ADDRESS_60999]. 
Missed study intervention dose
The planned double -blind tre atment phase starts at randomization and ends at week 52 or the 
study  treatment end date (i.e. [ADDRESS_61000] participant of the study has been 
randomized), whichever is earlier, or when stud y drug is permanentl y discontinued. Study  
drug will star t immediately after randomization (day  1), and is expected to continue through 
the end of the planned treatment period as described above.
If a dose of study  intervention is missed , the participant should take a dose immediately  on the 
same day . The dose should not be doubled to make up for a missed dose. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  32of 86
Table 6–1Study interventions
Arm name [CONTACT_55865] 2433334 
low doseBAY 2433334 
medium doseBAY 2433334 
high dosePlacebo
Intervention Name [CONTACT_55865] 2433334 BAY 2433334 BAY 2433334 Placebo
Type Drug Drug Drug Placebo
Dose formulation Tablet Tablet Tablet Tablet
Unit dose strengths 5 mg 5 mg and 15 mg 25 mg NA
Dosage Level(s) 10mg 20mg 50mg NA
Frequency Once a day in 
the morningOnce a day in 
the morningOnce a day in 
the morningOnce a day in 
the morning
Route of 
AdministrationOral Oral Oral Oral
Use experimental Experimental experimental Placebo
IMP/A xMP IMP IMP IMP IMP
Packaging and 
LabelingHDPE bottles 
with desiccant 
capsuleHDPE bottles 
with desiccant 
capsuleHDPE bottles 
with desiccant 
capsuleHDPE bottles 
with desiccant 
capsule
Abbreviation: AxMP = auxiliary medicinal product; IMP= investigational medical product; NA= not 
applicable
All study  interventions will be labelled according to the requirements of local regulations .
For all administered study  interventions a system of numbering in accordance with all 
requirements of Good Manufacturing Practice (GMP) will be used, ensuring that each dose 
can be traced back to the respective bulk batch of the ingredients.
A complete record of batch numbers and expi[INVESTIGATOR_55840]’s study  file.
In all cases BAY [ADDRESS_61001] of care, consisting of 
antiplatelet therap y. The choice of antipla telet therapy  will be left to the discretion of the 
treating ph ysician and can include single or dual antiplatelet therap y(see section 6.5.1).
The choice of b ackground antiplatelet therap y will be documented in the patient records and 
capture d in the eCRF .
6.2 Preparation /Handling / Storage / Accountability
All study  interventions will be stored at the investigational site in accordance with Good 
Clinical Practice (GCP) and Good Manufacturing Practice (GMP) requirements and the 
instructions given b y the clinical supplies department of the sponsor or its affiliates. 
1. The investigator or designee must confirm appropriate temperature conditions have 
been m aintained during transit for all study  intervention received and any  
discrepancies are reported and resolved before use of the study  intervention.
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply or administer study  intervention. All study  
intervention must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and auth orized site staff.
3.The investigator, institution, or the head of the medical institution (where applicable) is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (i.e. receipt, reconciliation, and final disposition re cords).
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  33of 86
4.Further guidance and information for the final disposition of unused study  
interventions are provided in the I nvestigator Site File. 
6.3 Measures to Minimize Bias: Randomization and Blinding
All participants will be centrally  assigned to randomized study  intervention using an 
Interactive Web Response Sy stem (I WRS). To accomplish random assignments, computer -
generated randomization lists specified by [CONTACT_456]'s responsible statistician will be 
prepared b y Randomization Management at the study spons or. The randomization lists are 
provided to an I WRS vendor. Before the study  is initiated, the log in information & directions 
for the IWRS will be provided to each site.
The randomization will be stratified based on whether participants will receive single or dual 
antiplatelet therap y after the index stroke and randomization.
Study  intervention will be dispensed at the study  visits summarized in SoA (see Section 1.3). 
Returned study intervention should not be re -dispensed to the participants.
Participants will be randomly  assigned in a [1:1:1:1 ]ratio to receive stud y intervention . 
Investigators will remain blinded to each participant’s assigned st udy intervention throughout 
the course of the study . 
Tablets containing 5 mg, 15 mg or 25 mg of BAY 2344443 and corresponding placebo are 
identical in appearance (size, color, shape). In order to maintain the blind, study  interventions 
will be packaged in bottles labeled with a unique number which will be preprinted on each 
bottle. In addition, participants will be provided with 2 bottles either with active drug or 
placebo depending on the randomization outcome.
6.3.1 Unblinding
The I WRS will be programmed with blind -breaking instructions. In case of an emergency , the 
investigator has the responsibility  for determining if unblinding of a participant’s treatment 
assignment is warranted. If the investigator is unavailable, and a treating physician not associated wi th the study requests emergency unblinding, the emergency  unblinding requests 
are forwarded to the study  specific emergency  medical advice 24 hours/[ADDRESS_61002] the sponsor prior to unblinding a participant’s treatment assignment unless this could delay  emergency  treatment of the participant. If a participan t’s treatment assignment is 
unblinded, the sponsor must be notified within [ADDRESS_61003] be recorded in the source documentation and case report form, as applicable. 
BAY2433334 is known to prolong the activated partial thromboplastin time (aPTT) in a dose 
depende ntmanner.  a PTT is a commonly  used functional coagulation test widely  used in 
clinic al practice in patients using anticoagulants and is as well commonly  used during acute 
hospi[INVESTIGATOR_602], and as a pre-procedur al screening test.  Thus, inadvertent unblinding of the 
participant or investigator might take place in cases where aPTT test results are known. 
Therefore, the measurement of aPTT during the study  conduct is strongl y discouraged and 
should only  be done in case of (emergency ) situations where aPTT may help to guide 
treatme nt decision.  a PTT determinations obtained as part of the stud y protocol will not be 
reported to investigators during the study in order to maintain the blinding.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  34of [ADDRESS_61004] 
questioning. At each dispensing visit (V6, V8 and V10) and at EO T (V12 ) orET(V12a ) visit, 
compliance will be assessed by  [CONTACT_21442]/capsules . Deviation(s) from the 
prescribed dosage regimen should be recorded in the eCRF.
To monitor compliance, the investigator will be required to document drug dispensing and 
return for each participant. Overall compliance with study  intervention intake should be 
between 80% and 120% of the scheduled dose at the end of stud y drug treatment. The date of 
dispensing the stud y intervention to the participant will be documented. Study  intervention 
will be dispensed according to the schedule provided in the SoA ( Section 1.3).
Participants should be instructed to bring all unused study drug and empt y packages at study  
Visit 6, 810 and EO T (or ET) visit if applicable for accountability  purposes. Any  
discrepancies between actual and expected amount of returned stud y medication must be 
discussed with the participant at the time of the visit, and any  explanation must be 
documented in the source documents.
6.5 Prior and Concomitant Therapy
Any relevant medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of enrollment or receives during the study  must be rec orded along with:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
Careful recording of medication received during the index event is required especiall y 
any thrombol ysis and antithrombotic medication
The Medical Monitor (sponsor’s Study  Medical Expert) should be contact[CONTACT_43205] y 
questions regarding concomitant or prior therap y.
Special focus needs to be on antiplatelet , thrombol yticsand anticoagulant medications. A ny 
useof thes e medications in the week before the index stroke event, prior to screening , as well 
asconcomitant use from study  entry  until the last scheduled study  visit of the participant, 
needs to be captured on the specified concomitant medication page.
The concomitant use of NSAID therap y during the study is strongl y discouraged since this has 
been shown to increase the risk of gastrointestinal (GI) bleeding. However, if a NSAID drug 
must be temporarily  used, it is recommended that the lowest possible dosage for the shortest 
duration possible, be selected, not to exceed 4 weeks. Should analgesics be needed, use of paracetamol/acetaminophen is recommended. 
Concomitant therapy with any of the following drugs is prohibited from 14 days (or at least 
five hal f-lives of the active substance, whatever is longer) before first study intervention 
administration, until at least [ADDRESS_61005] study  intervention administration:
Strong inhibitors of cy tochrome P450 isoenzy me 3A4 (CYP3A4) e.g. human 
immunodeficiency  virus protease inhibitors (ritonavir, indinavir, nelfinavir, atazanavir, 
or saquinavir), s ystemically  used azole antim ycotic agents (ketoconazole, itraconazole, 
voriconazole, or posaconazole), clarithrom ycin, telithromy cin
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  35of 86
Strong inducers of CYP3A4, e.g. phen ytoin, carbamazepi[INVESTIGATOR_050], phenobarbital, 
rifampi[INVESTIGATOR_2513], or St. John’s wort
A separate complete list with prohibited medications will be provided to the investigator.
6.5.1 Concomitant Antiplatelet Therapy
The choice of antiplatelet therap y as standa rdofcare background treatment during the study  
treatment period will be left to the discretion of the investigators and /or treating ph ysician and 
should follow local standard of care guidelines. Antiplatelet therap ycan include single and 
dual therap y with ASA, clopi[INVESTIGATOR_7745], dipy ridamole or cilostazol. D ual antiplatelet therap y 
with ASA and clopi[INVESTIGATOR_55841]. 
Anticipated use of a nticoagulants or/and other drugs that affect the coagulation sy stem and 
specificall y drugs that affect platelets other than the allowed background therap y exclude 
participation . 
6.5.[ADDRESS_61006] Bleeding During 
the Study
If a participant ha s serious bleeding during the study  treatment period that requires 
hospi[INVESTIGATOR_059], the following routine measures should be considered:
Temporaril y or permanently discontinue the randomized study  medication. The 
decision to discontinue study  drug, tempora rily or permanentl y, will be at the 
discretion of the treating physician and must be documented.
Temporaril y discontinue antiplatelet therapi[INVESTIGATOR_55842] y 
controlled , based upon the discretion of the treating phy sician.
Invest igate other causes of serious bleeding such as coagulopathies, thrombocy topenia, 
kidney /liver d ysfunction, or other concomitant medications. 
Consider usual supportive treatments for bleeding, including local control of bleeding 
through standard procedures based upon the bleeding location, fluid replacement, 
blood transfusion, and fresh frozen plasma (FFP) transfusion. Consideration may also be given to the use of an antifibrinoly tic agent, such as tranexamic acid or ε -amino 
caproic acid ( Tomaselli et al. 2017).
If bleeding cannot be controlled by [CONTACT_55874], consider urgent surgical or 
non-surgical procedures to stop the bleeding (emergency  surgery , arterial 
embolization, endoscopic cauterization, etc.) and unblinding of the randomized 
treatment assignment.
For those participants treated with BAY 2433334, administration of the procoagulants can
also be considered , but there are no definite data in the support of use of these agents.
6.5.[ADDRESS_61007] Surgery or 
Percutaneous/ Endoscopic Procedures 
When possible, surgery  and percutaneous/endoscopic procedures should be planned and 
delay ed for at least 24 hours to allow for a 24 -hour washout period after temporary  
disconti nuation of randomized study  drug to mitigate risks of bleeding.
For urgent or emergent surgery  or percutaneous/endoscopic procedures, when waiting for [ADDRESS_61008] the urgency  of the procedure 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  36of 86
based upon the clinical situation. Peri- procedure management may  in part, depend on the 
randomized treatment assignment ( BAY 2433334 or placebo) and unblinding of treatment 
assignment may  be necessary . In general, the treatment recommendations should follow the 
Guidelines for Severe Perioperative Bleeding Management ( Kozek- Langenecker et al. 2013 ). 
The procedure should be conducted in such a way  to minimize the risk of bleeding.
Treatment of participants receiving BAY 2433334 during urgent or emergency  procedures 
may be guided by  [CONTACT_55875] . Apart 
from giving FXI concentrate (FXI) as replacement therapy to cover a surgical bleeding event 
(Ling et al. 2016 ), there have been reports in the literature about the successful use of 
tranexamic acid or ε -amino caproic acid for the management of the se patients with a FXI 
deficiency  when undergoing surgery  (Duga and Salomon 2013) . More detailed information 
may be found in the Investigator’s Brochure.
6.5.[ADDRESS_61009] 24- hour cardiac rh ythm monitoring, and 
echocardiograph y is encouraged (but neither required by  [CONTACT_55876] ). 
The treatment assignment may  have to be emergently  unblinded if necessary ,to facilitate 
management decisions (e.g. intravenous thromboly sisor intra -arterial thromboly sis in case of 
mechanical clot removal) .
For particip ants with acute ischemic stroke who are receiving BAY 2433334, the risk of 
bleeding with use of intravenous thromboly sis is unknown and has not been studied; hence a 
clear recommendation in this situation cannot be given. However, it is not recommended that 
a thromboly tic agent be given unless it is known that the study  intervention ( BAY 2433334 )
has not been taken in the previous 48 hours, and the aPTT is normal. In this case, the risk of 
bleeding associated with thrombol ysis is not expected to be increased (and unblinding may  
not be necessary ).
For participant s who undergo thromboly sis; study  medication should be withheld until at least 
24 hours after thrombolysis.
Mechanical clot removal (thrombectom y) without thrombolys is may  be performed in any  
case.
6.5.5 Guidance for Management of Participants who Experience new
Myocardial Infarction During the Study
For participant s who experience a suspected new, acute cardiac ischemic event requiring 
unplanned hospi[INVESTIGATOR_059] (unstable a ngina or acute MI), standard of care medications should 
be administered according to local practice guidelines and based upon the chosen invasive procedure (dual antiplatelet therap y, if not alread y being used, intravenous / subcutaneous 
anticoagulants, or intravenous antiplatelet therapi[INVESTIGATOR_55843]/IIIa inhibitors or 
cangrelor). Study  drug should be temporaril y discontinued upon hospi[INVESTIGATOR_55844] a 
suspected acute cardiac ischemic event to mitigate potential bleeding risks. Cardiac ischemic 
event (acute MI) endpoint reporting guidelines and processes should be followed for these situations.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  37of 86
For participant s who undergo urgent or emergent coronary  angiography  (with or without PCI ) 
as treatment for the new ischemic event, stud y drug sh ould be restarted no earlier than 24 
hours after the arterial sheath has been removed and  / or no earlier than [ADDRESS_61010] 
dose of intravenous  / subcutaneous anticoagulant or intravenous antiplatelet agent has been 
administered. For participants who are treated with urgent or emergent CABG surgery for the 
new ischemic event after coronary  angiography , study  drug should be stopped (if possible) [ADDRESS_61011]-surgical drains 
(ches t tubes) have been removed.
The treatment assignment may  have to be emergently  unblinded to facilitate decisions 
regarding treatment with intravenous fibrinol ytics for acute ST- elevation MI. For participant s 
who are receiving BAY 2433334, the risk of bleeding related to the concomitant use of an intravenous fibrinol ytic is unknown and has not been studied. For participant s treated with 
intravenous fibrinol ytics, study  drug should be restarted no earlier than 24 hours after 
receiving fibrinol ytics.
6.6 Dose Modi fication
This protocol does not allow an y alteration from the outlined dosing schedule (Section 4.3).
6.7 Intervention after the End of the Study
No further study  intervention is planned following the End of the Study . For the definition of 
“End of Study ” please refer to Section 4.4. 
Any further therapy  at the end of the study  is at the discretion of investigator/treating 
physician. 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/W ithdrawal 
7.1 Discontinuation of Study Intervention 
In rare instances, it may  be necessary  for a participant to permanently discontinue (definitive 
discontinuation) study  intervention. If stud y intervention is definitively discontinued, the 
participant will r emain in the study  to be evaluated for bleeding and efficacy  outcome events 
until the planned regular end of treatment. See the SoA for data to be collected at the time of 
discontinuation of study  intervention and follow -up and for an y further evaluations that need 
to be completed.
An ET visit is only  applicable to participants who prematurel y discontinue intake of study 
intervention; such participants should undergo the ET visit as soon as possible, after 
permanent discontinuation of study  intervention. A safet y follow up visit (telephone call) will 
occur 14 day s after the day  of the premature discontinuation of study  intervention (+ 7days 
window). If the ET visit falls into the time window for the safet y follow up visit ( ≥ 2weeks 
after permanent discontinuation of study  intervention), a safety  follow up visit will not be 
performed.In this stud y, outcome events and vital status data are crucial to the primary anal ysis and must 
be collected until the end of the study , as participants will still be part of the study  even if they
are no longer taking study medication. Therefore, all efforts will be taken to motivate 
participants to comply  with all study  procedures and to continue to be followed until the end 
of the study for each participant ( i.e. 26 to 52 weeks) .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  38of [ADDRESS_61012] :
Requirement of full dose and long term anticoagulat ion therap y during study conduct 
(e.g., de novo atrial f ibrillation, pulmonary  embolism)
Strong CYP3A4 inhibitors as well as strong CYP3A4 inducers. 
Discontinuation of study  intervention for abnormal liver function should be considered by  [CONTACT_32845] a participant meets one of the conditions outlined below, or if the 
investigator believes that it is in best interest of the participant (please also refer to Section 
10.5 for the requirements for liver function monitoring).
ALT or AST >  [ADDRESS_61013] 
ALT or AST >  [ADDRESS_61014] for more than 2 weeks 
ALT or AST >  3 x UL N and (total bilirubin >  [ADDRESS_61015] or INR > 1.5) 
ALT or AST >  [ADDRESS_61016] with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and /  or eosinophilia (>  5%) 
See the SoA for data to be collected at the time of p remature intervention discontinuation (i .e, 
ET visit) and follow- up and for any further evaluations that need to be completed. 
At the time of permanent discontinuation of the study  intervention, the participant is expected 
to continue regular stud y clinic visits at the investigator’s site as outlined in the protocol.
If this is not possible for any  reason, the investigator and participant must discuss and 
determine further follow -up options, as listed below, in descending order of preference: 
1.Participant will be contact[CONTACT_55877] -up intervals
2. Participant allows his  / her treating ph ysician, e.g. general practitioner or a family  
member, to be contact[CONTACT_55878] -up interval, 
or at least once at study  end (if allowed in respective country ) 
3.Participant will be contact[CONTACT_55879] 
(planned regular EOT visit for the participant)
After permanent discontinuation of the study  intervention the following will need to be 
collected at the regular study visits and up to the regular end of treatment visit , preferentiall y 
directly  from the participant and as agreed to b y the participant during the initial informed 
consent process:
Vital Status
Antiplatelet and anticoagulant medications
Outcome events (M I, stroke, sy stemic embolism, death, bleeding) .
If a participant is unwilling or unable to return for follow- up visits in person or have follow -
up contacts, sites should collect as much follow -up visit information as possible, including 
contact[CONTACT_55880]’s representative, famil y member or treating 
physician b y telephone or by [CONTACT_2319]. If applicable, vital status may  be obtained by  [CONTACT_55881]. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  39of 86
participant’s medical or public sources (e.g. social media, health insurance, public [death] 
registry ), unless this process is not allowed by  [CONTACT_427].
Withdrawal of Consent
Note: None of the above options is considered a withdrawal of consent. 
A withdrawal of consent should only  occur in exceptional cases and means that the participant 
does not agree to an y kind of follow -up and specifically  refuses any  further contact [CONTACT_55882] (see Section 7.2).
7.1.1 Temporary Discontinuation 
In the event of a temporary  interruption of study  drug for an y reason, stud y drug will be 
restarted as soon as medically justified in the opi[INVESTIGATOR_871]. There is no 
predefined maximum limit for temporary  treatment interruption. 
If study  interventions were temporari lystoppe d, PK/PD blood samples should only  be 
obtained if study  interventions have been restarted and sustained for at least 4 day s.
7.2 Participant Discontinuation/Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioral, 
compliance, or administrative reasons. Thi s is expected to be uncommon.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit 
should be conducted, as shown in the SoA. See the SoA for data to be collected at the 
time of study  discontinuation and follow -up and for any further evaluations that need 
to be completed.
The participant will be permanently discontinued both from the study intervention and 
from the study  at that time.
If the participant withdraws consent for disclosure of future information, the sponsor may retain and continue to use an y data collected before such a withdrawal of consent.
At the time of informed consent, participants will be explained all the options to continue in the study  after permanent discontinuation of study  intervention (see 
Section 7.1). This will be re -discussed at the time of permanent discontinuation of 
study  intervention and the participant’s specific agreement will be documented. 
Participants will agree to be contact[CONTACT_55883]- up information should they  
decide to stop the intervention.
When a participant withdraws consent from study  participation before completing the 
study , meaning that the participant does not agree to any  kind of follow -up and 
specificall y refuses an y further contact [CONTACT_44502], the reason for consent 
withdrawal is to be documented in the source document. Public information can be 
used to obtain vital status for these participants where allowed by  [CONTACT_427].
7.[ADDRESS_61017] to follow- up if he or she repeatedl y (twice) fails to return 
for scheduled visits and is unable to be contact[CONTACT_17066]. 
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  40of 86
The site must attempt to contact [CONTACT_55884]/or should 
continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee must make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing address 
or local equivalent methods). These contact [CONTACT_21457]’s medical record.
Should the participant continue to be unreachable, he/ she will be considered lost to 
follow up.
In order to reduce risk for lost to follow -up the site should collect [ADDRESS_61018] details 
should be checked regularly  at the stud y visits.
A patient locator service may be used to re -establish contact [CONTACT_4490] a participant in case 
the site has exhausted all means of regaining contact, if the participant will agree to 
this in the I CF.
8. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA (Section 1.3). Protocol 
waiv ers or exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a scr eening log 
to record details of all participants screened and to confirm eligibility  or record reasons 
for screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management (e .g., 
blood count) and obtained bef ore signing of the ICF may  be utilized for screening or 
baseline purposes provided the procedures met the protocol- specified criteria and were 
performed within the time frame defined in the SoA.
8.1 Efficacy Assessments 
The efficacy  assessments include primar yandsecondary  endpoints of the study  (see 
Section 3).
8.1.1 Primary efficacy endpoint
The primary  efficacy  endpoint is the composite of sy mptomatic ischemic stroke and covert
brain infarcts detected by [CONTACT_9268] .
A definition of the primary  efficacy  outcome events is provided as follows, and further 
specified in the charter of the clinical event committee (CEC) . Details on the time periods for 
collecting Outcome Events information are reported in Section 10.8.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  41of 86
[IP_ADDRESS] Stroke
Stroke is defined as an acute epi[INVESTIGATOR_55845] d ysfunction caused b y an
injury  of the brain, spi[INVESTIGATOR_1831], or retina as a result of hemorrhage or infarction.
Differentiation is made regarding ischemic stroke and hemorrhagic stroke.
Hemorrhagic stroke :
Hemorrhagic stroke is defined as an acute, atraumatic extravasation of blood into the brain 
parench yma, intraventricular or subarachnoid space with associated neurological sy mptoms. 
This does not include microbleeds nor hemorrhagic transformation of an ischemic stroke. 
Ischemic stroke:
Either of the following is considered to be an ischemic stroke: 
Rapid onset (or present on awakening) of a new focal neurological deficit with clinical 
(>24 hours s ymptoms/signs) or imaging evidence of infarction that is not attributable 
to a non-ischemic cause (i.e. not associated with infection, tumor, seizure, severe 
metabolic disease) 
Acute worsening of an existing focal neurological deficit (e.g., the qualify ing stroke) 
that is judged to be attributable to a new infarction or extension of the previous infarction in the same vascular territory, based on persisting s ymptoms/signs or 
imaging evidence of infarction and no evidence of a non -ischemic eti ology . If imaging 
is inconclusive, persistent sy mptoms/signs must be significant (worsening of NIHSS 
score of 4 or more) and sustained (duration of ≥24 hours or until death).
The term undetermined stroke will apply  when sudden focal neurological deficits persist for 
24 hours (or death if occur sbefore 24 hours) ,but without neuroimaging or autopsy .
[IP_ADDRESS].[ADDRESS_61019]. MRI  criteria for brain 
infarction will be available in the MRI  procedure s manual.
8.1.2 Secondary efficacy endpoint s
A definition of the secondary  efficacy  outcome events is provided as follows, and further 
specified in the charter of th e clinical event committee (CEC).
Secondary  efficacy  endpoints are:
composite of sy mptomatic ischemic stroke and covert brain infarcts detected by  [CONTACT_9268], 
CV death, my ocardial infarction and s ystemic embolism
symptomatic ischemic stroke
covert brain infarcts detected b y MRI
symptomatic ischemic stroke, CV death, m yocardial infarction 
symptomatic ischemic and hemorrhagic stroke 
disabling stroke (mRS ≥4)
all-cause mortality .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  42of 86
[IP_ADDRESS] Systemic Embolism
Systemic embolism is defined as abrupt vascular insufficiency  assoc iated with clinical or 
radiological evidence of arterial occlusion in the absence of other likel y mechanisms (this 
does not include thromboembolism of the pulmonary  vasculature or venous thrombosis, e.g. 
pulmonary  embolism or deep venous thrombosis).
[IP_ADDRESS] Myoca rdial Infarction
The term acute m yocardial infarction (MI) is used when there is evidence of myocardial 
necrosis in a clinical setting consistent with acute my ocardial ischemia. According to the M I 
Universal Definition from 2018 ( Thygesen e t al. 2018 ) the diagnosis of MI requires the 
combination of:
Presence of acute my ocardial injury  (changes in cardiac biomarkers) and
Evidence of acute m yocardial ischemia derived from the clinical presentation, 
electrocardiographic changes, or the results of m yocardial or coronary  artery imaging, 
or in case of post -mortem pathological findings irrespective of biomarker values
[IP_ADDRESS] Cardiovascular Death
Cardiovascular death includes death due to stroke, my ocardial infarction, heart failure or 
cardiogenic shock, sudden death or any other death due to other cardiovascular causes.  In 
addition, death due to non- traumatic hemorrhage will be included.
8.2 Safety Assessments 
The safet y assessments in clude primary , secondary  and exploratory  endpoints of the study . At 
each visit during the study as specified in the SoA, the investig ator will evaluate the 
participant for the occurrence of bleeding events. All necessary  information to classify  
bleeding events according to the ISTH, the Thromboly sis In M yocardial Infarction (TIM I) and 
the Bleeding Academic Research Consortium (BARC) cri teria will be collected in the CRF.  
8.2.1 Primary safety endpoint
The primary  safet y endpoint includes the anal ysis of the composite of ISTH major bleeding 
(Section [IP_ADDRESS]) and clinically  relevant non-major bleeding (Section [IP_ADDRESS] ).
[IP_ADDRESS] ISTH Major Bleeding
An event that meets at least one of the below criteria for a major bleeding e vent according to 
the definition given b y the I STH:
Fatal bleeding, and/or
Symptomatic  bleeding in a critical area or organ (intracranial, intraocular, intraspi[INVESTIGATOR_1304], 
pericardial, retroperitoneal, intraarticular, or intramuscular with compartment 
syndrome), and/or 
Clinically  overt* bleeding associated with a recent decrease in the hemoglobin level of 
≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value 
available before the event, and/or 
Clinically  overt* bleeding leading to transfusi on of 2 or more units of packed red 
blood cells or whole blood
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  43of 86
*overt bleeding requires the identification of the bleeding location and the hemoglobin 
drop and/ or transfusion needs to be related to the bleeding
[IP_ADDRESS] ISTH Clinically Relevant Non- Major Bleeding
Clinically  relevant non- major bleeding is considered an y sign or sy mptom of hemorrhage that 
does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of 
the following criteria (Kaatz et al. 2015):
requiring medical inte rvention by  a healthcare professional
leading to hospi[INVESTIGATOR_3820]
prompting a face to face (i.e. not just a telephone or electronic communication) 
evaluation
8.2.2 Secondary safety endpoints
The secondary  safet y endpoints include the analysis of the following outcome events:
all bleeding
ISTH major bleeding (Section [IP_ADDRESS])
ISTH CRNM bleeding (Section [IP_ADDRESS])
ISTH minor bleeding (Section [IP_ADDRESS])
Intracerebral hemorrhage (non -traumatic)
[IP_ADDRESS] ISTH Minor bleeding
Allother overt bleeding epi[INVESTIGATOR_55846] I STH major or clinicall y 
relevant non- major bleeding will be classified as minor bleeding (e.g. bleeding from a minor 
wound that does not prompt a face -to-face evaluation for a phy sical exam ination or laboratory  
testing) .
8.2.3 Exploratory safety endpoint
The exploratory  safet y endpoints include the analysis of the following outcome events:
TIMI clinicall y significant bleeding
TIMI major bleeding
TIMI minor bleeding
BARC bleeding definition Ty pe 2, 3, 5
BARC bleeding definition Ty pe 3, 5
BARC bleeding definition Type 1, 2, 3, 5
[IP_ADDRESS] TIMI Bleeding Definitions
The non- CABG related TI MI clinicall y significant bleeding definition encompasses the 
following bleeding t ypes excluding events that are related to a CABG procedure:
TIMI Major Bleeding
Any symptomatic intracranial hemorrhage
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  44of 86
Clinically  overt signs of hemorrhage (including imaging) associated with a 
drop in hemoglobin of ≥ 5 g/dL (or when the hemoglobin concentration was 
not available, an absolute drop in hematocrit of ≥ 15%).
Fatal bleeding (bleeding that directly  results in death within 7 day s)
TIMI Minor Bleeding
Any clinically  overt sign of hemorrhage (including imaging) that was 
associated with a fall in hemoglobin concentration of 3 to <  5 g/d L (or, 
when hemoglobin concentration was not available, a fall in hematocrit of 
10 to <  15%).
TIMI Bleeding Events Requiring Medical Attention
Any bleeding event that required medical treatment, surgical treatment, or 
laboratory  evaluation and did not meet criteria for a major or minor 
bleeding event, as defined above.
In addition to TI MI significant bleeding also TI MI major bleeding and TIMI  minor bleeding 
will be anal yzed (Chesebro et al. 1987 ).
[IP_ADDRESS] BARC Bleeding Definition
The BARC bleeding definition encompasses the following bleeding t ypes (type 4: CABG -
related bleeding is not applicable to this study ):
Type 0: no bleeding
Type 1: bleeding that is not actionable and does not cause the patient to see k 
unscheduled performance of studies, hospi[INVESTIGATOR_059], or treatment b y a healthcare 
professional; may  include epi[INVESTIGATOR_15664]- discontinuation of medical therap y 
by [CONTACT_15743] a healthcare professional
Type 2: any  overt, actiona ble sign of hemorrhage (e.g. more bleeding than would be 
expected for a clinical circumstance, including bleeding found b y imaging alone) that 
does not fit the criteria for ty pe 3, or [ADDRESS_61020] one of the following 
criteria: (1) requiring no nsurgical, medical intervention by  a healthcare professional, 
(2) leading to hospi[INVESTIGATOR_3820], or (3) prompting evaluation
Type 3:
Type 3a
Overt bleeding plus hemoglobin drop of 3 to <  5 g/dL* (provided 
hemoglobin drop is related to bleed)
Any transfusion with overt bleeding
Type 3b
Overt bleeding plus hemoglobin drop ≥ 5 g/dL* (provided hemoglobin 
drop is related to bleed)
Cardiac tamponade
Bleeding requiring surgical intervention for control (excluding 
dental/nasal/skin/hemorrhoi d)
Bleeding requiring intravenous vasoactive agents
Type 3c
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  45of 86
Intracranial hemorrhage (does not include microbleeds or hemorrhagic
transformation, does include intraspi[INVESTIGATOR_1304]); subcategories confirmed b y 
autopsy  or imaging or lumbar puncture
Intraocular bleed compromising vision
Type 5: fatal bleeding
Type 5a
Probable fatal bleeding; no autopsy  or imaging confirmation but clinically  
suspi[INVESTIGATOR_55847] 5b
Definite fatal bleeding; overt bleeding or autopsy  or imaging confirmation
*Corrected for transfusion (1 U packed red blood cells or 1 U whole blood  = 1g/dL
  hemo globin)
8.2.4 Physical Examinations
Height and weight (also referred to as biometrics in the SoA) will be measured and 
recorded at screening (see Section 1.3).
8.2.5 Vital Signs
Blood pressure and pulse measurements will be assessed with a completel y automated 
device. Manual techniques will be used only if an automated device is not available.
Blood pre ssure and pulse measurements should be preceded by  [CONTACT_2669] [ADDRESS_61021] for the participant in a quiet setting without distractions (eg, television, cell 
phones).
Vital signs will be measured in a semi- supi[INVESTIGATOR_55848] [ADDRESS_61022] and will 
include temperature, s ystolic and diastolic blood pressure, and pulse .
8.2.6 Electrocardiograms
A single 12-lead ECG will be obtained as outlined in the SoA (see Section 1.3) using 
an ECG machine that automatically  calculates the heart rate and measures PR, QRS, 
QT, and QTc intervals.
8.2.7 Clinical Safety Laboratory Assessments
See Section 10.[ADDRESS_61023] of clinical laboratory tests to be performed and to the SoA 
for the timing and frequency . 
The investigator must review the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the AE section of the 
CRF. The laboratory  reports must be filed with the source documents. Clinically  
significant abnormal laboratory  findings are those which are not associated with the 
underly ing disease, unless judged by  [CONTACT_55885]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_61024] dose of stud y intervention 
should be repeated until the values return to normal or baseline or are no longer considered clinically  significant by  [CONTACT_55886] .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  46of 86
oIf such values do not return to normal/baseline within a period of t ime judged 
reasonable b y the investigator, the etiology should be identified and the sponsor 
notified.
oAll protocol -required laboratory  assessments, as defined in Section 10.2, must be 
conducted in accordance with the laboratory  manual and the SoA. 
oIf laboratory  values from non -protocol specified laboratory  assessments performed 
at the institution’s local laboratory  require a change in participant m anagement or 
are considered clinically  significant b y the investigator (e .g., SAE or AE or dose 
modification), then the results must be recorded in the CRF. 
8.[ADDRESS_61025] (AESI) for the study are specified in 
Section 8.3.7.
AEs that are outcome events according to the study protocol are further described in Section 
8.3.6 and Section 10.3.5.
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or the 
participant's legall y authorized representative).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE. They  remain responsible for 
following up SAEs, or AEs considered related to the study  intervention or s tudy procedures, 
or those that caused the participant to discontinue the study  intervention and/or study .AESIs 
have to be followed up regardless of causality  or relationship to study intervention.
8.3.1 Time Period and Frequency for Collecting AE and SAE Inform ation 
All SAEs will be collected from the start of intervention ( first day  of study  intervention 
intake )until the safet y follow -up visit ,at the time points specified in the SoA (Section 1.3).
All AEs will be collected from the start of the intervention until the follow -up visit at the time 
points specified in the SoA (Section 1.3).
Medical occurrences that begin before the start of study  intervention but after obtaining 
informed consent will be recorded on the Medical History /Current Medical Conditions section 
of the case r eport form (CRF) not the AE section.
All SAEs will be recorded and reported to the sponsor or designee immediately and under no circumstances should this exceed 24 hours after the investigator becomes aware of this event, as indicated in Section 10.3 . The investigator will submit any  updated SAE data to the 
sponsor within 24 hours of it being available.
Investigators are not obligated to activel y seek AE or SAE after conclusion of the study  
participation. However, if the investigator learns of an y SAE, including a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the st udy intervention or study  participation, the investigator must 
promptly  notify  the sponsor. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  47of 86
8.3.2 Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE and SAE and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences. 
8.3.3 Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs, and serious and non- serious AEs of 
special interest (as defined in Section 8.3.7), will be followed until resolution, stabilization, 
the event is otherwise explained, or the participant is lost to follow -up (as defined in Section 
7.3). Further information on follow -up procedures is provided in Section 10.3. 
8.3.4 Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a nSAE is essential so that 
legal obligations and ethical responsibilities towards the safet y of participants and the 
safet y of a stud y intervention under clinical investigation are met. 
The sponsor has a legal responsibility  to notify  both the local regula tory authority  and 
other regulatory  agencies about the safet y of a study  intervention under clinical 
investigation. The sponsor will comply  with country -specific regulatory  requirements 
relating to safet y reporting to the regulatory  authority , Institutiona l Review Boards 
(IRB)/Independent Ethics Committees (I EC), and investigators.
For all studies except those utilizing medical devices investigator safet y reports must 
be prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local regulatory  requirements and sponsor policy  and forwarded to investigators as 
necessary .
An investigator who receives an investigator safety report describing a nSAE or other 
specific safet y information (e .g., summary  or listing of SAEs) from the sponsor wi ll 
review and then file it along with the Investigator’s Brochure and will notify  the 
IRB/IEC, if appropriate according to local requirements.
8.3.5 Pregnancy
Details of all pregnancies in female partners of male participants will be collected after 
the start of study  intervention and until [ADDRESS_61026] dose intake .
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours
of learning of the pregnancy  and should follow the procedures outlined in Section 
10.4.
Abnormal pregnancy  outcomes (e .g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAEs.
8.3.6 Disease-Related Even ts
During the study  there will be incidences where AEs are also potential efficacy  or safet y 
endpoints.
In compliance with applicable regulations, in the event of a S[LOCATION_003]R related to the blinded 
treatment, the participant’s treatment code will usually  be unblinded before reporting to the 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  48of 86
Health Authorities. Notifications of IECs  / IRBs and investigators will be done according to 
all applicable regulations (see Section 8.3.4).
The following disease -and treatment -related events are common in participants with stroke 
who are being treated with an anticoagulant :
a.Bleeding
b.Death
c.Myocardial Infarction
d.Ischemic stroke
e.Systemic embolism
These events will be recorded on the corresponding CRF page in the participant’s CRF.
These events will also be monitored and adjudicated by  a Central Event Committee (CEC) on 
an ongoing basis. In addition, these events require reporting to the sponsor according to the standard process of 
expedited reporting of SAEs within 24 hours of the investigator’s awareness of the event, 
along the timelines set for reporting of SAEs and AESI s.
However, due to their expectedness, efficacy  endpoints listed above (b- e: death, my ocardial 
infarction, ischemic stroke and s ystemic embolism), including events indicative of those 
outcome events (e.g. TIA, cardiac chest pain), will not be subject to sy stematic unblinding and 
expedited S[LOCATION_003]R reporting to Health Authorities. 
8.3.[ADDRESS_61027] (AESIs) will be all AEs related to hepato -biliary  
dysfunction, i.e. relevant increases in the respective liver lab values (ALT >  [ADDRESS_61028]  > 3 x UL N, with confirmatory  re-testing within 5 day sof the initial laboratory  value 
elevation) with or without sy mptoms such as e.g. nausea, vomiting, right upper quadrant 
abdominal pain, fatigue, weakness, weight loss and jaundice. Re -testing of lab values can be 
performe d at the local lab and needs to be documented in the eCRF.
AESI s have to be reported to the sponsor within 24 hours of the investigator’s awareness, i.e. 
along the timelines set for SAEs (even though they may  not be classified as serious) , as 
described in Section 8.3.1 .
8.4 Treatment of Overdose
For this study , any  dose of BAY 2433334 greater than 3 assigned dail y doses (i.e. more than 6 
tablets) within a 24-hour time period will be considered an overdose.
The s ponsor does not recommend specific treatment for an overdose of BAY 2433334, as a 
specific antidote for the study  drug is not available. The use of activated charcoal to reduce 
absorption may  be considered.
Due to the mechanism of action, an overdose of the study  drug could potentially  result in 
hemorrhage. In case of bleeding linked to overdose the guidance on bleeding management as 
found in S ection 6.5.1 should be followed.
In the event of an overdose, the investigator/treating ph ysician should:
Contact [CONTACT_27465] .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  49of 86
Closely  monitor the participant for an y AE/SAE and labora tory abnormalities until 
study  drug can no longer be detected sy stemically  (at least 5 day s.). 
Document the quantit y of the excess dose as well as the duration of the overdose in the 
CRF.
Decisions regarding dose interruptions or modifications will be mad e by [CONTACT_55887].
8.5 Pharmacokinetics
For the investigation of systemic exposure to BAY 2433334 and its relationship with 
treatment effects, the plasma concentra tions of BAY 2433334 and optionally  of its metabolite 
M-10 (BAY 2826102) will be determined at different time points using a sparse sampling 
approach in all  participants. Details about the collection, processing, storage and shipment of samples will be pr ovided separately  (e.g. in the l aboratory  manual). Stud y personnel 
responsible for bioanaly tics will be unblinded and will have access to the randomization list. 
Analy sis of samples from participants not treated with BAY 2433334 is optional. 
Blood samples will be collected at the time points indicated in the SoA (Section 1.3). PK 
samples obtained at additional time points based on the investigator’s discretion will not qualify  as a protocol deviation and will be used for PK analy sis as well. Deviations from the 
specified sampling intervals will be documented and taken into ac count for the PK anal ysis. 
Date and time of the PK sample collection and date and time of the most recent study  
intervention intake ( ie, both of the PK/PD sampling day , and of the day  before that ) must be 
documented.
At Visit [ADDRESS_61029] -dose samples will be taken like 
indicated in the SoA (Section 1.3).The PK data and the relationship of the BAY 2433334 exposure parameters (e.g. C
max, AUC) 
with treatment effects might be evaluated using population approaches (e.g. non -linear mixed 
effect modeling) including potential influence of relevant partic ipant co-variables. Anal ysis 
and report will be done under a separate cover. This evaluation might be started prior to 
database lock: if this is applicable, appropriate measures will be taken to maintain blinding of the study  team. 
PK samples will be anal yzed u sing validated analytical methods. Quality control (QC) and 
calibration samples will be anal yzed concurrently with study  samples. The results of 
calibration samples and QC samples will be reported in the Bioanal ytical Report which will 
be included in the C SR for this study .
8.6 Pharmacodynamics
Blood sampling for PD parameters is scheduled for the time points as given in Section 1.3. 
The actual date and time of blood sampling will be documented in the eCRF. 
AllPDparameters will be measured using validated methods.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  50of 86
Quality  control and calibration samples will be analy zed concurrently  with study  samples. For 
selected PD parameters , the results of QC samples will be reported together with analy te 
concentrations in the Clinical Study  Report (CSR) of this study .
Concentrations of the analy te are calculated according to the m ethod description. Detailed 
method descriptions of all PD methods will be filed with the study  report.
The following parameters will be used to assess the PD effects after administration of the 
investigational drug , but will be performed optionally  and/or onl y in a subset of participants :
aPTT will be measured using a coagulation assay  via kaolin -trigger
Activated Factor XIa activity  (AXIA) will be analy zed using a kaolin -trigger and a 
fluorogenic substrate readout
D-Dimer will be measured using an immunoturbidometric method
Fibrinogen will be measured using a coagulation assay
FXI concentration will be measured via ELISA using pol yclonal antibodies
Factor XII activity  will be assessed with an aPTT -based coagulation test using FXII-
deficient plasma. Factor X II concentration will be anal yzed using an enzyme -linked 
immunosorbent assay  (ELISA) .
vWF antigen level and vWF ristocetin cofactor (i.e. vWF functional activity ) will be 
analyzed using turbidometric assays.
The study  sponsors reserve the right not to conduct all or part of the above mentioned 
analyses.
In addition, blood samples will be taken for exploratory  biomarker work (see Section 8.8).
Detailed informatio n about the collection, processing, storage and shipment of the samples 
will be provided separately  (e.g. sample handling sheets and / or laboratory manual).
8.7 Genetics
Genetic as well as non -genetic analy ses will be part of the biomarker investigations in this 
study . See Section 8.8 for details.
8.8 Biomarkers
Exploratory  biomarker analy ses (scheduled for the time points as given in Section 1.3), that 
might be performed optionally  and/or onl y in a subset of partic ipants are:
NT-proBNP will be measured using an electrocheminulescence assay  (ECLIA)
hsCRP will be measured using an immunoturbidometric method
Thrombin- activatable fibrinoly sis inhibitor (TAFI) and C1 inhibitor activity  will be 
measured using chromogenic substrate assay s
TAT and F1.2 will be analy zed using immunoassay s
In addition to the biomarkers described above , further biomarkers related to the mode of 
action or the safet y of BAY 2433334 and similar drugs may  be examined. The same applies to 
further biomarkers deemed relevant to cardiovascular diseases and associated health 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  51of 86
problems. These investigations may  include e.g. diagnostic, safet y, PD, monitoring, or 
potentially  predictive biomarkers. 
Those additional anal yses may  include genetic as well as non- genetic biomarkers. Genetic 
investigations may  be of any  kind, except for whole genome sequencing. Results will be
reported under separate cover, if the evaluations are performed.
Details on the collection, processing, storage, and shipment of biomarker samples will be 
provided in separate documents (e.g., sample handling sheets or lab oratory manual). Samples 
may be stored for a maximum of 15 y ears (or according to local regulations) following the 
end of the stud y at a facility  selected by  [CONTACT_55888].
8.9 Immunogenicity Assessments
Not applicable.
8.10 Health Economics /Medical Resource Utilization and Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are not evaluated in this study . 
9. Statistical Considerations
9.[ADDRESS_61030] (evidence 
for effectiveness) based on the incidence proportions observed for the primary  efficacy  
outcome at Day  180. To detect a dose -response signal, the null hy pothesis: “The response 
(incidence proportion) at all fo ur doses is equal” will be tested against the alternative “There 
is a dose- response relationship” for each of M=[ADDRESS_61031] per treatment group into 
account. For each of the   = 4 treatment arms (i.e. the place bo group and the 3 acti ve 
treatm ent arms of BAY 2433334) the response is denoted by   ,  =1,…,  .
For each model  ,   =1,…,3 , in the candidate set
the null hy pothesis    :  		  = [ADDRESS_61032]
the respective 1 -sided alternative h ypothesis    :  		  		>	0,
where  = (   ,…,   	)′is an optimized contrast vector for the doses 
  =    ,…,   		  =(  		(  ,  		),…,  		(  ,  		))′and is the dose -response 
model 	  = 	 ( , )+ . A more detailed description of the MCP -Mod approach and the 
models used will be provided in Section 9.4.2.
9.[ADDRESS_61033] across the 
doses, that is, detecting a statistically  significant dose response signal for the primary  efficacy  
outcome in this study  using the MCP -Mod approach.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  52of 86
Assuming a true incidence for the primary  efficacy outcome of 22.5% at Day  180 under 
placebo, a maximum relative risk reduction of 25% for BAY 2433334 relative to placebo, a 
set of plausible dose -response shapes including Emax and logistic models (chosen based on 
FXIa inhibition data, see Section 9.4.2), random allocation of participants to dose groups 
according to a 1:1:1:1 ratio and about 1% of participants without post -randomization data on 
the occurrence of the primary  outcome, a sample size of [ADDRESS_61034] 80% power to demonstrate a dose -response relationship, using a one- sided test at 
a type I error rate of α=0.10. Approximately  1900 patients will be screened to ach ieve 1800 
randomized participants for an estimated total of 450 evaluable participants per intervention group.
9.3 Populations for Analyses 
For purposes of analy sis, the following populations are defined:
Population Description
Enrolled All participants who sign the ICF .
Full Analysis Set All participants randomized to study drug.
Safety All participants randomly assigned to study intervention and 
who take at least [ADDRESS_61035] 1 valid plasma 
concentration and without protocol deviation, which would interfere with the evaluation of the PK data.
Abbreviations: ICF = Informed con sent form, PK = pharmacokinetic(s)
9.4 Statistical Analyses
9.4.1 General C onsiderations
The statistical anal ysis plan (SAP) will be developed and finalized before the first interim 
analysisand will describe the participant populations to be included in the anal yses, and 
procedures for accounting for missing, unused, and spurious data. This section is a summary  
of the planned statistical anal yses of the primary  and secondary  endpoints and estimands. For 
the intercurrent event “discontinuation of study  treatment ”the “ treatment policy ”strategy  is 
chosen for efficacy  estimands and the “while on treatment” strategy  is chosen for safet y 
estimands.
The intercurrent event ”death”will be handled w ith the “ while alive ”strategy .
Confidence intervals will be two-sided 90% confidence intervals. The cumulative incidence 
risk will be estimated for t ime to event variables .The hazard ratios and the corresponding 
confidence intervals will be estimated on separate Cox proportional hazards models for each 
comparison of a BAY 2433334 dose versus placebo . No comparison of the different doses of 
BAY 2433334 is planned.All collected events will be anal yzed summarized using methods like frequency  tables and 
other descriptive statistics.
Analy ses will be stratified will be stratified based on whether participants will receive single 
or dual antiplatelet therapy  after the index stroke and randomization .The statistical analy ses 
will be performed using SAS; the version used will be specified in the SAP.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  53of [ADDRESS_61036] -randomization MRI  performed to 
assess if s/he experienced a covert brain infarct before death. This data would be meaning ful 
for the analy sis but can no longer be collected due to death. The same holds true for 
participants who refuse to undergo a second MRI and/or that have a missing MRI at 
randomization.For the main estimator corresponding to the primary  efficacy  estimand missing values for 
covert infarcts detected by  [CONTACT_55889] 26 will be handled as follows: 
For participants in Part A who have a MRI at week 13, the result of that MRI  will be used if a 
covert infarct was detected.
For participants without a symptomatic stroke and missing MRI  evaluation (up to or) at week 
[ADDRESS_61037] is the same as in participants without a symptomatic stroke with a MRI  evaluation at week 26 (Quan et al. 
2007). 
The MCP -Mod method combining MCP (multiple comparison procedu res) principles with 
modeling techniques will be used for the primary  statistical analy sis. This method allows the 
flexibility  of modeling for dose estimation, while preserving the robustness to model 
misspecification associated with MCP procedures.3 acti ve doses of BAY 2433334 will be used in this study : 10 mg, 20 mg, and 50 mg, with an 
additional placebo arm, corresponding to a 0 mg dose. The incidence proportion at dose   will 
be transformed to a normal distributed variable  
 , the estimated log it of the incidence
proportion at dose  . For the dose -response relationship the functional relationship is
  = ( , )+ .
It is assumed that the relative incidence risk is 22.5% at Day  180 under placebo and there is a 
relative risk reduction of 25% under the highest dose .
The candidate set of models for  ( , ) consists of three models, two (standardized) Emax 
models with parameter     = 6 and     = 29 and a (standardized) logistic model with the 
parameter     = 0.05and   = 8.25. All three candidate models assume a monotonicall y 
decreasing dose -response. The parameter of the models are based on pharmacokinetic data. 
The dose-response candidate models are shown in the Table below.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  54of 86
Model Response as function of dose d
Emax1 –1.24 – 0.40d / ( 6+ d)
Emax2 –1.24 – 0. 57d / (29 + d)
Logistic –0.88 – 0.72d / (1 + exp((0.05 - d) / 8.25))
The corresponding dose -response relationships of the candidate models are shown in the 
Figure below.
Based on these models and the observed data optimal contrasts   and the corresponding 
critical value will be calculated. (For a detailed description see the SAP ).
Based on the optimal contrast and the critical values a one- sided test with   =0.[ADDRESS_61038] model can be 
selected for the next step: modeling and estimation. The selection of the dose -estimation 
model will be based on an assessment of the p value. If no candidate model is statistically  
significant, the procedure stops indicating that a dose-response relationship cannot be 
established from the observed data. The modelling of the dose -response relationship wi ll be 
done using least -squares parameter estimation.
For the primary  efficacy  estimand sensitivity  analy ses are planned to investigate the impaction 
of potentially missing values due to missing MRI scans. Assumptions made for participants 
with a missing MR I are described in the following:
1.Assume these participants had no covert infarct.
2.Assume these participants hada covert infarct.
3.Assume only  those participants in theBAY [ADDRESS_61039] (worst 
case anal ysis).
As supplementary analy sis only the participants who have a MRI at randomization and at 
week 26will be anal yzed, i.e. the population in the primary  efficacy  estimand is changed.

CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  55of [ADDRESS_61040] ratio of the composite of International Society  on 
Thrombosis and Hemostasis (ISTH) major bleeding and clinicall y relevant non -major 
(CRNM) bleeding comparing pooled BAY [ADDRESS_61041] intake of stud y drug up until 2 days after permanent study drug discontinuation will 
be counted. As supplementary  anal yses the ana lyses will be done on the ITT data set and 
counting all events from randomization until final follow-up.
These analy ses will be replicated for the comparison of each dose of BAY 2433334 and 
placeb o.
In addition, incidence proportions for the primary safet y endpoint will be reported.
9.4.3 Secondary Endpoints
Efficacy analyse s
The secondary  efficacy analy ses for theendpoints that include the evaluation of the MRI will 
be different from those that will be performed forthe endpoints thatdo not include it. 
The secondary  efficacy  estimand for the following endpoints:
composite of sy mptomatic ischemic stroke and covert brain infarcts detected by  [CONTACT_9268], 
CV death, my ocardial infarction and s ystemic embolism
covert brain infarcts detected b y MRI 
is the incidence in 6months of each of the individual endpoints following a non -
cardioembolic ischemic stroke in adult participants treated with antiplatelet therap ywhile 
alive and regardless of treatment discontinuation, for each of the different doses of BAY 2433334 and placebo.
The secondary  efficacy  estimand for the following endpoints:
symptomatic ischemic stroke
symptomatic ischemic stroke, CV death, m yocardial infarction 
symptomatic ischemic and hemorrhagic stroke
disabling stroke (mRS ≥4)
all-cause mortality
is the hazard ratio of each of the individual endpoints following a non- cardioembolic ischemic 
stroke in adult participants treated with antiplatelet ther apy,while alive and regardless of 
treatment discontinuation, comparing each of the different doses of BAY 2433334 with 
placebo. The endpoints will be anal yzed with point estimators and confidence intervals for the 
propor tionof participants with an event.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  56of [ADDRESS_61042] one dose of study medication of BAY 2433334 or 
placebo and while the pa rticipant is alive and exposed to study  drug for the endpoint s:
all bleeding
ISTH major bleeding
ISTH CRNM bleeding
ISTH minor bleeding
Intracerebral hemorrhage (non -traumatic) .
The anal yzes will follow those of the primary  safety  estimand.
9.4.4 Tertiary/exploratory Analy ses
Exploratory  safety  endpoints are: TIMI clinically  significant bleeding, TIMI major bleeding, 
TIMI minor bleeding , BARC bleeding definition Ty pe 2, 3, 5 , BARC bleeding definition 
Type 3, 5 and BARC bleeding definition Ty pe 1, 2, 3, 5 .
Exploratory  other endpoints are FXIa inhi bition, aPTT and various biomarkers.
The anal yses of these endpoints will be specified in the SAP.
9.4.5 Other Safety A nalyses
Adverse Events (AE) will be anal yzed by [CONTACT_9086], such as frequency tables. All 
AEs will be tabulated according to the af fected s ystem organ class and preferred term, as 
coded b y the medical dictionary for regulatory  affairs (MedDRA).
9.4.6 Other Analyses 
PK, as well as the manda tory pharmacod ynamic markers will be described in the statistical 
analysis plan finalized before database lock. Optional pharmacod ynamic markers as well as 
exploratory  biomarkers may  be describe d in the statistical analy sis plan finalized before 
database loc k, if they  are available in time. Otherwise they  may  be reported under separate 
cover. The population PK anal ysis and exploratory  or optional biomarkers may be presented 
separately  from the main clinical study  report (CSR).
9.[ADDRESS_61043] party , i.e. the 
statistical analy sis center (SAC ) that supports the IDMC and thus, is independent of the study  
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  57of 86
team and the sponsor. A small group of academic leaders (Executive Committee) including 
the heads of the three Steering Committees that have been established for the individual 
studies and sponsor representatives will participate in the review of these data. IDMC members may  also be included in this review. The data will be kept strictly  confidential by  
[CONTACT_55890]. Thus, the study  integrit y 
will not be impacted and the study  conduct will otherwise not be altered by [CONTACT_55891].
The interim anal ysis will include selected and predefined study  data primarily  as aggregated 
data for this individual study  but may  also includ e pooling of some data across all [ADDRESS_61044] interim anal ysis will be conducted o nce about 50% of the participants (800 
participants) with a minor non- cardioembolic ischemic stroke (NIHSS ≤ 7) are enrolled in the 
study  or [ADDRESS_61045] 12.5% of participants (200 participants). 
If the review confirms the safet y profile of BAY 2433334 and raises no concern regarding 
(intracranial) hemorrhage or hemorrhagic transformation of the ischemic stroke , Part B of the 
study  will be initiated, during which from then on participants with more severe cases of 
stroke (NIHSS ≥ 8 and ≤ 15) can also be included as well as participants after thromboly sis or 
endovascular therap y (mechanical thrombectom y). Even though the p rimary  focus for the
interim analy sis is specific for the decision for th is study  only, data and especiall y bleeding 
data from the other 2 studies will be taken into consideration. The second interim analysis will occur when sufficient data are available from all 3 Phase 2 
studies. This interim analysis may  occur, when approximately  80% of all planned participants, 
taken all [ADDRESS_61046] dose (in case of an unexpected 
higher bleeding rate in the highest dose or in the combination with antiplatelet therap y) or 
addition of a lower or higher dose or replacement of one dose (in case of a difference i n 
pharmacokinetics or PD parameters such as inhibition of FXIa in the patient populations 
compared to healthy  volunteers).
9.6 Independent Data Monitoring Committee (IDMC)
An independent data monitoring committee (IDMC) will be involved in the review of the efficacy  and safet y data for study [ZIP_CODE], and of the overall safet y data across all 3 Phase 2 
studies with BAY 2433334 (Section [IP_ADDRESS]). Detailed information on the roles and responsibilities of the IDMC will be described in the IDMC Charter. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  58of 86
10. Supporting Documentation and Operational Considerations
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1 Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the 
following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines
 Applicable ICH Good Clinical Practice (GCP) Guidelines
 Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Br ochure, and other relevant 
documents (e .g., advertisements) must be submitted to an IRB/IEC by  [CONTACT_55892]/IEC before the study  is initiated. 
Any amendments to the protocol will require IRB/I EC approval before 
implementation of changes made to the stud y design, except for changes necessary to 
eliminate an immediate hazard to study  participants. Any substantial modification of 
the protocol will be submitted to the competent authorities as substantial amendments for approval, in accordance with ICH Good Clinical Practice and national and 
international regulations.
The investigator will be responsible for the following:
 Providing written summaries of the status of the study  to the IRB/IEC annually  
or more frequentl y inaccordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/IEC
 Notify ing the IRB/IEC of SAEs or other significant safet y findings as required 
by [CONTACT_1744]/IEC procedures
 Providing oversight of the conduct of the stud y at the site and adhe rence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local regulations
10.1.2 Financial Disclosure
Investigators and sub- investigators will provide the sponsor wi th sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3 Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorize d representative and answer all questions 
regarding the stud y. 
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative will be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  59of [ADDRESS_61047] (HIPAA) requirements, where 
applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written inform ed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must also 
sign the ICF.
Participants must be re -consented to the most current version of the ICF(s) during their 
participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s legall y 
authorized representative. 
If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any  data collected before such a withdrawal of consent. 
Pharmacogenetic samples will be taken during the study . Study  participants will be 
asked to sign a separa te informed consent for pharmacogenetic research. 
10.1.4 Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant name s or any  information which would make the participant identifiable 
will not be transferred. 
The participant must be informed that his/her personal study -related data will be used 
by [CONTACT_10999]. The level of di sclosure 
must also be explained to the participant who will be required to give consent for their 
data to be used as described in the informed consent. 
The participant must be informed that his/her medical records may  be examined by  
[CONTACT_55893], by  [CONTACT_6667]/IEC members, and by  [CONTACT_55894].
10.1.5 Committees Structure
[IP_ADDRESS] Executive Committee
The Executive Committee, which consists of external experts in the area of neurology  and 
cardiology and will include the Steering Committee heads of the 3 Phase 2 studies with BAY 
2433334, as well as 2 sponsor representatives, will ensure the overarching integrit y of the 3 
studies. Details of the committee will be specified in the Executive Committee Charter. 
[IP_ADDRESS] Steering Committee (SC)
The main task of the Steering Committee is to support protocol development, to facilitate the 
conduct of the stud y,to advise the sponsor on clinical, medical, and scientific questions and to
initiate publications. The Steering Committee will consist of the National Leaders from the 
participating countries, three physicians from the clinical coordinating center (Population 
Health Research Institute , Canada ), the director of the MRI  Core Lab, a nd two Bay er 
representative s. Additional details of the committee will be specified in the Steering 
Committee charter.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  60of 86
[IP_ADDRESS] IDMC
Ongoing safet y monitoring during the conduct of the study will be performed by [CONTACT_55895]. An independent statis tical anal ysis center (SAC) will be involved in 
processing unblinded safety  data for the IDMC. Analy sis periods and procedures will be 
defined in an operational charter (IDMC Charter) filed in the study  file. Following data 
review, the IDMC will provide wr itten recommendations that will be transferred to Bay er. All 
other definitions will be provided in the IDMC charter.
[IP_ADDRESS] Clinical Events Committee (CEC)
Potential pre -specified clinical outcome events will be submitted for adjudication to an 
independent CEC. Adjudication of all bleeding events as well as efficacy  events will be 
performed b y members of the CEC who will review events in a blinded fashion and will 
adjudicate and classify  the following events in a consistent and unbiased manner according to 
definit ions contained in the CEC charter. The adjudication will also include algorithm 
approaches:
Bleeding events according to the following classifications:
ISTH (major, clinicall y relevant non- major and minor)
TIMI (major, minor, requiring medical attention, minimal)
BARC (t ype 1, 2, 3, 5)
Death (CV death [including death with unknown cause] or non- CV death)
MI
Stroke (ischemic, hemorrhagic, undetermined)
Systemic embolism
In addition, events that might be indicative of a potential outcome event will be reported as 
outcome events to ensure that no outcome event is missed. This includes for example TIA and hospi[INVESTIGATOR_55849].
Data entry  procedures and documentation necessary  for case adjudication will also be 
described in the CEC charter. Adjudication results will be the basis for the final anal ysis.
10.1.6 Dissemination of Clinical Study Data
Result summaries of Bayer's sponsored clinical studies in drug development Phases 2, 3 and 4 and Phase 1 studies in patients are provided in the Bay er Trial Finder application after 
marketing authorization approval in line with the position of the global pharmaceutical industry  associat ions laid down in the "Joint Position on the Disclosure of Clinical Trial 
Information via Clinical Trial Registries and Databases". In addition results of clinical drug 
trials will be provided on the publicly  funded website www.ClinicalTrials.gov and EU 
Clinical Trials Register in line with the applicable regulations.
Bayer commits to sharing upon request from qualified scientific and medical researchers 
patient -level clinical trial data, study -level clinical trial data, and protocols from clinical trials 
in patients for medicines and indications approved in the [LOCATION_002] (US) and European 
Union (EU) on or after 01 JAN 2014 as necessary for conducting legitimate research. 
All Bay er-sponsored clinical trials are considered for publication in the scientif ic literature 
irrespective of whether the results of the clinical trials are positive or negative.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  61of 86
10.1.7 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the sponsor or designee electronically  (e.g., laboratory data). The 
investigator is responsible for verify ing that data entries are accurate and correct by  
[CONTACT_55896] y or electronically signing the CRF. 
The investigator must maintain accurate documentation (source data) that sup ports the 
information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
Monitoring details describing strategy  (e.g., risk- based initiatives in operations and 
quality  such as Risk Management and Mitigation Strategies and Anal ytical Risk -Based 
Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (ce ntral, remote, or on -site 
monitoring) are provided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data. 
The sponsor assumes accountability  for actions delegated to oth er individuals (e .g., 
Contract Research Organizations).
Study  monitors will perform ongoing source data verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and 
verifiable from source documents; that t he safet y and rights of participants are being 
protected; and that the study  is being conducted in accordance with the currentl y 
approved protocol and any other stud y agreements, I CH GCP, and all applicable 
regulatory  requirements. 
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained b y the investigator for 15years after study  completion unless local 
regulations or institutional policies require a longer retention period. No records may  
be destro yed during the retention period without the written approval of the sponsor. 
No records may  be transferred to another location or part y without written notification 
to the sponsor. 
If the participant withdraw consent for disclosure of future information, the sponso r 
may retain and continue to use any  data collected before such a withdrawal of consent.
[IP_ADDRESS] Data Recording
The data collection tool for this study  will be a validated electronic data capture sy stem called 
TrialMaster . Participant data necessary  for analy sis and reporting will be entered/transmitted 
into a validated database or data s ystem ( SPECTRUM).
Data required according to this protocol will be recorded b y stud y site personnel via data entry 
into the interne t based EDC software s ystem TrialMaster, which t he ARO (Academic 
Research Organization) has licensed f rom OmniComm . TrialMaster has been validated b y 
OmniComm and the ARO for use in its clinical studies. TrialMaster allows for the application 
of software logic to set- up data entry  screens and data checks to ensure the completeness and 
accuracy  of the data entered by  [CONTACT_14523]. Bay er/ARO extensively  applies the logic to 
ensure data are complete and reflect the clinical data requirements of the study . Data queries 
resulting from the application of the software logic are resolved b y the site personnel. The 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  62of [ADDRESS_61048] facility  maintained by  [CONTACT_55897] a periodic basis 
to Bay er's internal computer sy stem via a secure Virtual Private Network.
All access to the TrialMa stersystem is through a password- protected security  system that is 
part of the TrialMaster software. All internal Bay er and external investigator site personnel 
seeking access must go through a thorough TrialMaster training process before they  are 
granted access to TrialMaster for use in Bay er's clinical studies. Training records are 
maintained.
All personnel with access to the TrialMaster system are supported b y a Service Desk staffed 
with trained personnel to answer questions and ensure access is maintained such that data 
entry can proceed in a timely  manner.
The TrialMaster System contains a s ystem-generated audit trail that captures an y changes 
made to a data field, including who made the change, why  the change was made and the date 
and time it was made . This information is available both at the investigator’s site and at 
ARO/ Bayer. Data entries made in the TrialMaster EDC screens are supported by  [CONTACT_55898] .
Data recorded from screening failur es
At minimum, the following data should be recorded in the CRF:
Demographic information (participant number; year of birth /age; sex; if applicable 
race / ethnicity )
Date of informed consent
Relevant inclusion/exclusion criteria
Reason for premature discontinuation
Date of last visit.
These data will be transferred to the respective database.
[IP_ADDRESS] Monitoring
In accordance with applicable regulations, GCP, and sponsor’s procedures, monitors will contact [CONTACT_8977] y to review wit h the site staff the protocol, study  
requirements, and their responsibilities to satisfy  regulatory , ethical, and sponsor’s 
requirements. When reviewing data collection procedures, the discussion will also include identification and documentation of source data items.
Thesponsor /designee will monitor the site activity  to verify  that the:
Data are authentic, accurate and complete.Supporting data may  be requested (example: blood glucose readings to support a 
diagnosis of diabetes). 
Safety  and rights of par ticipants are being protected
Study  is conducted in accordance with the currently  approved protocol
(including stud y treatment being used in accordance with the protocol)
Any other study  agreements, GCP, and all applicable regulatory requirements are met.
The investigator and the head of the medical institution (where applicable) agrees to allow the monitor direct access to all relevant documents.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  63of 86
[IP_ADDRESS] Data processing
Data will be collected as described in Section [IP_ADDRESS] . Clinical data management will be 
performed in accordance with applicable sponsor’s standards and data cleaning procedures. 
This is applicable for data recorded on eCRF as well as for data fro m other sources (e.g. I xRS, 
laboratory , adjudication committees).
For data coding (e.g. AEs, medication), internationally  recognized and accepted dictionaries 
will be used.
After its initial release for biometrical anal ysis, additional data release for ana lysis is possible, 
to include, for example, the following data: pharmacokinetic data, pharmacody namic data, 
anti-drug antibod y data etc.
[IP_ADDRESS] Missing data
All efforts will be made to collect complete data for all participants randomized in this study . 
Participa nts will be followed up to the study  end and all required data will be collected, 
regardless of participants’ compliance with stud y drug use or the visit schedule. 
Data from participants who prematurel y terminate the study  will be used to the maximum 
extent possible. All missing or partial data will be presented in the participant data listing as 
they are recorded in the eCRF. Data are collected primarily  through an EDC sy stem, which 
allows ongoing data entry and monitoring.
[IP_ADDRESS] Audit and inspection
To ensure compliance with GCP and regulatory  requirements, a member of the sponsor’s 
quality  assurance unit may  arrange to conduct an audit to assess the performance of the study  
at the study  site and of the study  documents originating there. The investigator/institution will 
be informed of the audit outcome.In addition, inspections by [CONTACT_8993](s)/I RB(s) are 
possible. The investigator should notify  the sponsor immediately  of any  such inspection.
The investigator/institution agrees to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the time of his/her staff to the auditor/inspector to discuss findings and an y issues. Audits and inspections may  occur at an y time during or af ter 
completion of the study .
[IP_ADDRESS] Archiving
Essential documents shall be archived safel y and securel y in such a way that ensures that they  
are readil y available upon authorities’ request.
Participant (hospi[INVESTIGATOR_307]) files will be archived according to local regulati ons and in accordance 
with the maximum period of time permitted by  [CONTACT_5035][INVESTIGATOR_307], institution or private practice. 
Where the archiving procedures do not meet the minimum timelines required by  [CONTACT_456], 
alternative arrangements must be made to ensure the availability  of the source documents for 
the required period.
The investigator/institution notifies the sponsor if the archival arrangements change 
(e.g. relocation or transfer of ownership).
The investigator site file is not to be destroy ed without the sp onsor’s approval.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  64of [ADDRESS_61049] with the investigator/institution will contain all regulations relevant for the stud y 
site.
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data co llected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
Definition of what constitutes source data can be found in the source data 
identification checklist.
The site must i mplement processes to ensure availability  of all required source 
documentation (e.g. participant file, local laboratory  report, etc.). A source document 
checklist (not part of this protocol) will be used at the site to identify  the source data 
for key  data points collected and the monitor will work with the site to complete this.
Race and ethnic group may  be entered directly  into the CRF, without availability  of 
corresponding source documentation. Thus, these CRF data will be the source and no 
additional source documentation will be available. For all other data, source documentation must be available at the site.
10.1.[ADDRESS_61050] been collected and a study -site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants by  [CONTACT_093]
Discontinuation of furth er study  intervention development
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory  authorities, and any  contract research 
organization(s) used in the study  of the reason for termination or suspension, as specified b y 
the applicable regulatory  requirements. The Investigator shall promptly  inform the participant
and should assure appropriate participant therapy  and/or follow -up.
10.1.10 Publication Policy
The results of this study  may  be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  65of 86
The sponsor will comply  with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the sponsor will generall y 
support publication of multicenter studies only  in their entir ety and not as 
individual site data. I n this case, a coordinating investigator [INVESTIGATOR_55850].
Authorship will be determined by  [CONTACT_11403] I nternational 
Committee of Medical Journal Editors authorship requirements.
10.2 Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 10–1 will be performed by [CONTACT_2237] . 
Protocol -specific requirements for inclusio n or exclusion of participants are detailed in 
Section 5 of the protocol.
Additional tests may  be performed at an y time during the study as determined 
necessary  by [CONTACT_43215].
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  66of 86
Table 10–1 Protocol -Required Safety Laboratory A ssessments
Laboratory 
AssessmentsParameters
Hematology Platelet Count RBC Indices:
MCV
MCH%Reticuloc ytesWhite blood cell (W BC) 
count with Differential:
NeutrophilsLymphocytes
Monoc ytes
Eosinophils
BasophilsRed blood cell (RBC) Count
Hemoglobin
Hematocrit
Clinical Chemistry1Aspartate Aminotransferase (AST)
Alanine Aminotransferase (ALT)Alkaline phosphatase (AP)Gamma glutam yl transpeptidase (γGT)
Bilirubin, total and direct
Lactate dehydrogenase (LDH)Creatinine kinase (CK)
Blood Urea Nitrogen (BUN)Creatinine
eGFR
Lipase
Amylase
SodiumPotassiumCalcium
Uric acidGlucoseCholesterol (total, HDL, LDL)Triglycerides
Albumin
Total proteinThyroid-stimulating hormone (TSH)
NOTES:
1 Details of liver chemistry  stoppi[INVESTIGATOR_21357] -up assessments after 
liver stoppi[INVESTIGATOR_31777] 7.1and Section10.5.
Abbreviations: ALT = alanine aminotransferase, AP = alkaline phosphatase, AST =aspartate 
aminotransferase, BUN = blood urea nitrogen, CK = creatinine kinase , eGFR = estimated glomerular filtration 
rate, γGT =gamma glutamyl transpeptidase, HDL =high-density lipoprotein, LDH = lactate dehydrogenase, 
LDL =low-density lipoprotein, MCH = mean corpuscular hemoglobin, MCV = mean corpuscular volume, 
RBC =red bloo d cell (count), TSH =thyroid -stimulating hormone, W BC=white blood cell (count)
Investigators must document their review of each laboratory  safet y report.
The name [CONTACT_55912]  [CONTACT_55899]. In the event of implausible results, the laboratory  may  
measure additional parameters to assess the quality of the sample (e.g. clotted or hemoly zed) 
and to verify  the results. The results from such additional analy ses may  neither be included in 
the clinical database of this study  nor evaluated further. If the results are relevant, the 
investigator will be informed to determine follow-up activities outside of this protocol. 
All exploratory  biomarkers are not used routinely  in practice and will be analy zed in batches. 
Therefore, timel y reporting of the results will not be possible during the study and review of 
the results will not assis t participant care.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  67of 86
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE 
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study participant, 
associated with the use of study  intervention, whether or not considered related to 
the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) associat ed 
with the use of study  intervention.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator (i.e., not 
related to progression of underly ing disease).
Exacerbation of a chronic or intermittent pre- existing condition including either 
an increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration 
even though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.
The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  
will be reported as AE or SAE if they  fulfil the definition of an AE or SAE. 
Also, “lack of efficacy” or “failure of expected pharmacological action” also constitutes an AE or SAE.
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  
[CONTACT_19448]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms 
of the disease/disorder being studied, unless more severe than expected for the participant’s condition.
Medical or surgical procedure (e.g., endoscop y, appendectom y): the condition 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  68of 86
that leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occu r (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , death 
due to progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a. Results in death
b. Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c. Requires inpatient hospi[INVESTIGATOR_1081]
In general, hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. 
If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d. Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel yminor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e .g., sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e. Is a congenital anomaly/birth defect
f. Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_55851]. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  69of 86
jeopardize the participant or may require medical or surgical intervention to prevent 
one of the other outcomes listed in the above definition. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
10.3.[ADDRESS_61051] ing and Follow -Up of AE and/or SAE 
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g. hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostics 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to the sponsor in lieu of completion of the AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y the sponsor. I n this case, all participant identifiers, with the exception 
of the participant number, will be redacted on the copi[INVESTIGATOR_55852].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensit y
The investigator will make an assessment of intensity for each AE and SAE reported during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal every day activities.
Severe: An event that prevents normal every day activities. An AE that is 
assessed as severe should not be confused wi th an SAE. Severe is a category  
utilized for rating the intensity  of an event; and both AEs and SAEs can be 
assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  70of 86
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to the sponsor.
The invest igator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements .
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully  as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized f ollow -
up period, the investigator will provide  with a copy  
of an y post mortem findings including histopathology. 
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours of 
receipt of the information.
10.3.4 Reporting of SAEs
SAE Reporting to the sponsor via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to the sponsor will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the electronic data collection tool will be 
[COMPANY_003]
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  71of 86
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or re ceives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form and 
transmit to 
Contacts for SAE reporting can be found in the Investigator Site File .
SAE Reporting to the Sponsor via Pape rCRF
SAE reporting via email transmission of the scanned paper CRF is the preferred 
method to transmit this information to the Sponsor via 
.  
In rare circumstances and in the absence of email transmission tools or facsimile 
equipment, notification by [CONTACT_9337] a cop y of the SAE data 
collection tool sent by  [CONTACT_22855].
Initial notification via telephone d oes not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in the Investigator Site File .
10.3.5 Event Reporting Process Overview 
If an AE or SAE is a potential outcome event (all bleeding, death, MI, stroke, TIA and 
systemic embolism [Section 8.3.6] ), itmust be collected and re ported on the dedicated forms 
on an ongoing basis, until the participant has completed the study . Thus , even if a participant 
is no longer taking stud y medication this would be until the end of the regular, planned end of 
treatment for this participant ( i.e. until the participant’s last visit). After completion of SFU 
visit, for participants that prematurel y discontinued study  intervention, there is no further 
requirement for reporting AEs. Only  potential outcome events are to be reported (refer to 
Section 8.3.1 and Section 10.9).
All bleeding events including fatal bleeding wil l be captured in the eCRF. SAE which are 
bleeding terms will also be reported to the sponsor’s PV Department in an expedited manner. Symptomatic intracerebral  / intraparench ymal hemorrhages as well as s ymptomatic 
subarachnoid hemorrhages will be captured a s bleeding and as stroke. All subdural  / epi[INVESTIGATOR_55853] y reported as bleeding.
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below).
[COMPANY_003]
[COMPANY_003]
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  72of 86
If fertility  is unclear (e.g. ,amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose o f study  intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP1.Premenarchal
2.Premenopausal female with 1 of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bi lateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (e.g. Müllerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documenta tion can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history  interview.
Postmenopausal Female
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause . 
A high follicle stimulating hormone (FSH) level in the postmenopausal range may  be 
used to confirm a postmenopausal state in women not using hormonal contraception or 
hormonal replacement therap y (HRT). However, in the absence of 12 months of 
amenorrhea , confirmation with more than one FSH measurement (>  40IU/L) is 
required. 
Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non-estrogen hormonal highl y effective contraception methods if they wish to 
continue thei r HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study  enrollment.
Contraception Guidance
Female participants must be of non -child bearing potential as per Clinical Trial 
Facilitation Group (CTFG) guidelines.
Male participants must agree to use condoms when sexually  active with a woman of 
childbearing potential from the time of the first dose to [ADDRESS_61052] dose of 
study  intervention. This is in line with the CTFG guideline, as BAY 2433334 is non 
genotoxic but data related to teratogenicit y/fetotoxicity  in early  pregnancy  (Segment 2 
studies) are not available at this stage of development. I n addition, all men must not 
donate sperm during the study .
Male Participants with Partners Who Become Pregnant 
The investigator will attempt to collect pregnancy  information on any  male 
participant’s female partner who becomes pregnant while the male participant is in this 
study . This applies onl y to male participants who receive stud y intervention.
After obtaining the necessary  signed informed consent from the pregnant female 
partner directl y, the investigator will record pregnancy information on the appropriate 
form and submit it to the sponsor within 24 hours of learning of the partner’s 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  73of 86
pregnan cy. The female partner will also be followed to determine the outcome of the 
pregnancy . Information on the status of the mother and child will be forwarded to the 
sponsor. Generally , the follow -up will be no longer than 6 to 8 weeks following the 
estimated delivery  date. Any  termination of the pregnancy  will be reported regardless 
of fetal status (presence or absence of anomalies) or indication for the procedure.
Female Participants Who Become Pregnant 
The investigator will collect pregnancy  information on any female participant who 
becomes pregnant while participating in this study. The initial information will be 
recorded on the appropriate form and submitted to the sponsor within 24 hours of 
learning of a participant's pregnancy . 
The participant will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow -up information on the participant and the neonate and 
the information will be forwarded to the sponsor. Generally , follow -up will not be 
required for longer than 6 to 8 weeks beyond the estimated delivery  date. Any  
termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  preg nancy  
complication or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. 
A spontaneous abortion (occurring at <22 weeks gestational age) or still birth 
(occurring at >22 weeks gestational age) is always considered to be an SAE and 
will be reported as such. 
Any post -study  pregnancy  related SAE considered reasonably related to the study  
intervention by  [CONTACT_55901] 
8.3.4. While the investigator is not obligated to actively  seek this information in 
former stud y participants, he or she may learn of an SAE through spontaneous 
reporting. 
Any female participant who becomes p regnant while participating in the study  will be 
withdrawn from the study.
10.5 Appendix 5: Liver Safety: Suggested Actions and Follow -up Assessments 
Any participant with an AL T or AST > [ADDRESS_61053] bilirubin, AP and INR , and will be assessed b y local laboratory. There als o 
should be inquiry  made about sy mptoms.
Every  effort should be made to clarify  the etiology  of elevated levels and laboratory  testing 
may include, but not be limited to, testing for viral hepatitis, cy tomegalovirus, Epstein -Barr 
virus, human immunodeficie ncy virus (once the participant has provided written consent), 
ferritin levels, iron, iron binding capacit y, antinuclear antibod y, and smooth muscle 
antibodies. Participant management is at the discretion of the treating ph ysician but the 
investigator may  continue the study  drug during retesting.
Liver function test monitoring should be performed as above for all participants with elevated 
ALT or AST >[ADDRESS_61054] normalized 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  74of 86
or returned to participant’ s baseline. If close liver monitoring is not possible, then the 
participant should discontinue study  medication.
For ALT or AST >  [ADDRESS_61055] concurrent with a total bilirubin > [ADDRESS_61056], every  effort should 
be made to promptly  clarify  any possible underl ying disease(s).
The frequency  of liver function tests based on re -test values is shown in Table 10–2. 
Table 10–[ADDRESS_61057] >  [ADDRESS_61058] ≤ [ADDRESS_61059] Once a week Until return to normal or participant baseline levels
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal
Discontinuation of treatment should be considered if: 
ALT or AST >  [ADDRESS_61060] 
ALT or AST >  [ADDRESS_61061] for more than 2 weeks 
ALT or AST >  [ADDRESS_61062] and (total bilirubin >  [ADDRESS_61063] orINR >  1.5) 
ALT or AST >  [ADDRESS_61064] with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and /  or eosinophilia (>  5%).
10.6 Appendix 6: Calculating the Child -Pugh Score
The severit y of liver disease ( Table 10–3) will determine the Child -Pugh score ( Table 10–4).
Table 10–3 Grading of severity of liver disease 
Factor +1 +2 +3
Bilirubin (mg/dL) < 2 2 – 3 > 3
Albumin (g/dL) > 3.5 2.8 –3.5 < 2.8
International Normalized Ratio < 1.7 1.7 –2.3 > 2.3
Ascites None Mild Moderate  / Severe
Encephalopathy None Grade I -II Grade III –IV
Source: adapted from (Pugh et al. 1973 )
Table 10–4 Child -Pugh score 
Child -Pugh Class A B C
Points 5 6 7 – 9 10 15
Source: adapted from (Pugh e t al. 1973 )
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  75of 86
10.7 Appendix 7: Calculating Glomerular Filtration Rate
In accordance with established nephrology  practice and guidelines, renal function at baseline 
and throughout the study  will be assessed by  [CONTACT_55902] 
(eGFR), calculated using the Modification of Diet in Renal Disease (MDRD) study  
abbreviated formula.
Isotope dilution mass spectroscopy (IDMS)- traceable MDRD Study Equation:
Conventional units (serum creatinine level is measured in mg/dL)
GFR (mL/min/1.73 m2) = 175 x (serum creatinine)-1.154x (Age)-0.203x (0.742 if female) x 
(1.212 if African American)GFR can be estimated using the calculator provided in the following link: 
http://www.kidney .org/professionals/kdoqi/gfr_calculator
For further information on assessing renal function using GFR estimates (Levey  et al. 2006 ).
10.8 Appendix 8: Outcome Events : Data Collection
All outcome events ( efficacy  and safet y) are to be captured and reported from randomization 
until the regular last scheduled study  visit  (ie, Safety  Follow -up Visit; in case of permanent 
discontinuation of study  intervention, the planned EOT visit). The eCRF will contain spe cific 
Outcome Event pages, as well as AEs subpages to capture the outcome events occurring throughout the study. The following points need to be considered when reporting outcome events.
Outcomes events occurring after randomization and before the first intake of the 
study intervention : the outcome event will be considered part of the medical history  
and should be reported in the outcome event eCRF page 
Outcomes events occurring after randomization and after first intake of study 
intervention and up to the SFU visit : the outcome event will be considered both AE 
and outcome event and should be reported in both in the AE page and in the AEs 
subpage for outcome events.
Outcome events occurring after SFU visit through the end of the study (for 
participant who d iscontinue study intervention): the outcome events should be 
collected until completion of participant´s regular scheduled stud y visits, and should 
be reported in the outcome event eCRF page.
10.9 Appendix 9: Study MRI procedure
The minimum requirements for the study  MRIs are outlined in the table below. In addition, it 
is encouraged to also collect T1 -and T2 weighted sequences and have a slice gap ≤ 1mm in 
order to detect smaller infarcts. However, this is optional and not required.
Minimum Requirements Preferred / Optional
Sequences FLAIR
DWI
ADC
SWI, SWAN, GRE or equivalent 
per local MRI routine protocolT1-weighted
T2-weighted
Field strengths ≥ 1 Tesla
Slice thickness 1 -5 mm
Slice gap ≤ 2 mm ≤ 1 mm
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  76of [ADDRESS_61065]. 
The study  MRIs will be transmitted to the central MRI  Core Lab that will be responsible for 
analyzing all MRIs blinded to treatment assignment.
More detailed information regarding image acquisi tion and processing will be found in a 
separate MRI  procedure s manual.
10.10 Appendix 10: Modified Ranking Score
Modified ranking score (mRS)
Score Description
0 No sy mptoms at all
1 No significant disability despi[INVESTIGATOR_55854]; despi[INVESTIGATOR_040] s ymptoms, able to carry 
out all usual duties and activities
2 Slight disability; unable to carry out all previous activities but able to look after 
own affairs without assistance
3 Moderate disability; requiring some help, but able to walk without assistance
4 Moderately sever e disability; unable to walk without assistance and unable to 
attend to own bodily needs without assistance
5 Severe disability; bedridden, incontinent and requiring constant nursing care and attention
6 Death
TOTAL (0–6): _______
Source: adapted from (Banks and Marotta 2007 , van Swieten et al. 1988 ).
10.11 Appendix 11: NIH Stroke Scale
NIH stroke scale (NIHSS)
Administer stroke scale items in the order listed. Record performance in each category  after 
each subscale exam. Do not go back and change scores. Follow directions provided for each 
exam technique. Scores should reflect what the patient does, not what the clinician thinks the patient can do. The clinician should record answers while administering the exam and work 
quickly . Except where indicated, the patient should not be coached (i.e., repeated requests to 
patient to make a special effort). At the end the scores of all items need to be su mmed up.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  77of 86
Instructions Scale Definition Score
1a. Level of Consciousness: The 
investigator must choose a response if a 
full evaluation is prevented by [CONTACT_55903], language barrier, orotracheal trauma/bandages. A 3 is scored only if the patient makes no movement (other than reflexive posturing) in response to noxious 
stimulation. 0
= Alert; keenly  responsive. 
1= Not alert ; but arousable by [CONTACT_55904], answer, or respond. 
2 = Not alert ; requires repeated 
stimulation to attend, or is obtunded and 
requires strong or painful stimulation t o 
make movements (not stereotyped). 
3 = Responds only with reflex motor or 
autonomic effects or totally unresponsive, 
flaccid, and are flexic.______
1b. LOC Questions: The patient is asked 
the month and his/her age. The answer must be correct -there is no partial credit 
for being close. Aphasic and stuporous patients who do not comprehend the 
questions will score 2. Patients unable to 
speak because of endotracheal intub ation, 
orotracheal trauma, severe dysarthria from any cause, language barrier, or any other problem not secondar y to aphasia are 
given a 1. It is important that only the initial 
answer be graded and that the examiner 
not "help" the patient with verbal or non -
verbal cues. 0
= Answers both questions correctly. 
1= Answers one question 
correctly. 
2= Answers neither question 
correctly. 
______
1c. LOC Commands: The patient is asked 
to open and close the eyes and then to grip and release the non -paretic hand. 
Substitute another one step command if 
the hands cannot be used. Credit is given 
if an unequivocal attempt is made but not completed due to weakness. If the patient 
does not respond to command, the task should be demonstrated to him or her (pantomime), and the result scored (i.e., 
follows none, one or two commands). 
Patients with trauma, amputation, or other physical impediments should be given suitable one- step commands. Only the first 
attempt is scored. 0
= Performs both tasks correctly. 
1= Performs one task correctly. 
2 = Performs neither task correctly. 
______
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  78of [ADDRESS_61066] Gaze: Only horizontal eye 
movements will be tested. Voluntary or 
reflexive (oculocephalic) eye movements 
will be scored, but caloric testing is not 
done. If the patient has a conjugate deviation of the eyes that can be overcome by [CONTACT_55905], the score 
will be 1. If a patient has an isolated 
peripheral nerve paresis (CN III, IV or VI), 
score a 1. Gaze is testable in all aphasic 
patients. Patients with ocular trauma, bandages, pre -existing blindness, or other 
disorder of visual acuity or fields should be tested with reflexive movements, and a 
choice made by [CONTACT_093]. 
Establishing eye contact [CONTACT_55906] a partial gaze pals y.0
= Normal. 
1= Partial gaze palsy; gaze is 
abnormal in one or both eyes, but forced deviation or t otal gaze paresis is not 
present. 
2= Forced deviation, or total 
gaze paresis not overcome by [CONTACT_55907]. 
______
3. Visual: Visual fields (upper and lower 
quadrants) are tested by [CONTACT_55908], 
using finger counting or visual threat, as
appropriate. Patients may be encouraged, but if they look at the side of the moving fingers appropriately, this can be scored as normal. If there is unilateral blindness or enucleation, visual fields in the remaining 
eye are scored. Score 1 only if a clear- cut 
asymme try, including quadrantanopia, is 
found. If patient is blind from any cause, 
score 3. Double simultaneous stimulation is performed at this point. If there is 
extinction, patient receives a 1, and the 
results are used to respond to item 11.0 = 
No visual loss. 
1 = Partial hemianopia. 
2 = Complete hemianopia. 
3 = Bilateral hemianopia (blind including 
cortical blindness). 
______
4. Facial Palsy: Ask –or use pantomime 
to encourage – the patient to show teeth or 
raise eyebrows and close eyes. Score symmetry  of grimace in response to 
noxious stimuli in the poorly responsive or 
non-comprehending patient. If facial 
trauma/bandages, orotracheal tube, t ape 
or other phy sical barriers obscure the face, 
these should be removed to the extent 
possible. 0 = 
Normal symme trical movements. 
1 = Minor paralysis (flattened nasolabial 
fold, asy mme try on smiling). 
2 = Partial paralysis (total or near -total 
paralysis of lower face). 
3 = Complete paralysis of one or both 
sides (absence of facial movement in the 
upper and lower face). ______
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  79of 86
Instructions Scale Definition Score
5. Motor A rm: The limb is placed in the 
appropriate position: extend the arms 
(palms down) 90 deg rees (if sitting) or 45 
degrees (if supi[INVESTIGATOR_050]). Drift is scored if the 
arm falls before [ADDRESS_61067] the score as untestable (UN), and clearly write the explanation for this choice. 0 = 
No drift; limb holds 90 (or 45) degrees 
for full 10 seconds. 
1 = Drift; limb holds 90 (or 45) degrees, 
but drifts down before full 10 seconds; 
does not hit bed or other support. 
2 = Some effort against gravity; limb 
cannot get to or maintain (if cued) 90 (or 
45) degrees, drifts down to bed, but has 
some effort against gr avity. 
3 = No effort against gravity; limb falls. 
4 = No movement. 
UN = Amputation or joint fusion, explain: 
_____________________ 
5a. Left A rm 
5b. Right A rm ______ 
______
6. Motor Leg: The limb is placed in the 
appropriate position: hold the leg at 30 
degrees (always tested supi[INVESTIGATOR_050]). Drift is scored if the leg falls before [ADDRESS_61068] the score as untestable (UN), and clearly write the explanation for this choice.0 = 
No drift; leg holds 30 -degree position 
for full 5 seconds. 
1 = Drift; legfalls by [CONTACT_2671] 5 -
second period but does not hit bed. 2 = Some effort against gravity; leg falls 
to bed by [ADDRESS_61069] gravity. 
3 = No effort against gravity; leg falls to 
bed immediately. 4 = No movement. 
UN = Amputation or joint fusion, explain: 
________________ 
6a. Left Leg 
6b. Right Leg ______ 
______
7. Limb A taxia: This item is aimed at 
finding evidence of a unilateral cerebellar 
lesion. Test with eyes open. In case of visual defect, ensure testing is done in intact visual field. The finger -nose -finger 
and heel -shin tests are performed on both 
sides, and ataxia is sc ored only if present 
out of proportion to weakness. Ataxia is absent in the patient who cannot understand or is paralyzed. Only in the 
case of amputation or joint fusion, the 
examiner should record the score as untestable (UN), and clearly write the explan ation for this choice. In case of 
blindness, test by [CONTACT_55909]. 0 = 
Absent. 
1 = Present in one limb. 
2 = Present in two limbs. 
UN = Amputation or joint fusion, explain: 
________________ 
______
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  80of 86
Instructions Scale Definition Score
8. Sensory: Sensation or grimace to 
pi[INVESTIGATOR_55855], or withdrawal from 
noxious stimulus in the obtunded or 
aphasic patient. Only sensory loss attributed to stroke is scored as abnormal and the examiner should test as many  
body  areas (arms [not hands] , legs, trunk, 
face) as needed to accurately check for 
hemisensory loss. A score of 2, “severe or 
total sensory loss,” should only be given 
when a severe or total loss of sensation can be clearly demonstrated. Stuporous and aphasic patients will, therefore, probably score 1 or 0. The patient with 
brainstem stroke who has bilateral loss of 
sensation is scored 2. If the patient does not respond and is quadriplegic, score 2. Patients in a coma (item 1a=3) are automatically given a 2 on this item. 0 = 
Normal; no sensory loss. 
1 = Mild-to-moderate sensory loss; 
patient feels pi[INVESTIGATOR_55856]; or there is a loss of superficial pain with pi[INVESTIGATOR_29107], but patient is aware of being touched. 
2 = Severe to total sensory loss; patie nt 
is not aware of being touched in the face, 
arm, and leg. ______
9. Best Language: A great deal of 
information about comprehension will be obtained during the preceding sections of 
the examination. For this scale item, the patient is asked to describe what is 
happening in the attached pi[INVESTIGATOR_1103], to name [CONTACT_55913]. Comprehension is judged from 
responses here, as well as to all of the commands in the preceding general neurological exam. If visual loss interferes with the tests, ask the patient to identify 
objects placed in the hand, repeat, and 
produce speech. The intubated patient should be asked to write. The patient in a coma (item 1a=3) will automatically score [ADDRESS_61070] choose a 
score for the patient with stupor or limited 
cooperation, but a score of 3 should be 
used only if the patient is mute and follows no one -step commands. 0 = 
No aphasia; normal. 
1 = Mild-to-moderate aphasia; some 
obvious loss of fluency or facility of comprehension, without significant 
limitation on ideas expressed or form of 
expression. Reduction of speech and/or comprehension, however, makes 
conversation about provided materials 
difficult or impossible. For example, in 
conversation about provided materials, 
examiner can identify pi[INVESTIGATOR_55857]’s response. 
2 = Severe aphasia; all communication is 
through fragmentary expression; great 
need for inference, questioning, and guessing b y the listener. Range of 
information that can be exchanged is limited; listener carries burden of 
communication. Examiner cannot identify 
materials provided from patient response. 
3 = Mute, global aphasia; no usable 
speech or auditor y com prehension. ______
10. Dysarthria: If patient is thought to be 
normal, an adequate sample of speech 
must be obtained by [CONTACT_55910]. If 
the patient has severe aphasia, the clarity 
of articulation of spontaneous speech canbe rated. Only if the patient is intubated or has other physical barriers to producing speech, the examiner should record the score as untestable (UN), and clearly write 
an explanation for this choice. Do not tell 
the patient why he or she is being tested . 0 = 
Normal. 
1 = Mild-to-moderate dysarthria; patient 
slurs at least some words and, at worst, can be understood with some difficulty. 
2 = Severe dysarthria; patient's speech is 
so slurred as to be unintelligible in the 
absence of or out of proportion to any dysphasia, or is mute/anarthric. 
UN = Intubated or other physical barrier, 
explain:__________________________________
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  81of 86
Instructions Scale Definition Score
11. Extinction and Inattention (formerly 
Neglect): Sufficient information to identify 
neglect may  be obtained during the prior 
testing. If the patient has a severe visual 
loss preventing visual double simultaneous stimulation, and the cutaneous stimuli arenormal, the score is normal. If the patient has aphasia but does appear to attend to 
both sides, the score is normal. The 
presence of visual spatial neglect or anosagnosia may  also be taken as 
evidence of abnormality. Since the abnormality is scored only if present, the 
item is never untestable. 0 = 
No abnormality. 
1 = Visual, tactile, auditory, spatial, or 
personal inattention or extinction to 
bilateral simultaneous stimulation in one of the sensor y modalities. 
2 = Profound hemi -inattention or 
extinction to more than one modality; 
does not recognize own hand or orients to 
only one side of space. ______
Source: adapted from ( Brott et al. 1989 , Lyden et al. 1994 , Pugh et al. 1973 )
10.12 Appendix 12: Abbreviations
AE Adverse Event
AESI Adverse event of special interest
ACC American College of Cardiology
AF Atrial fibrillation
AG Joint stock company , Aktiengesellschaft
AHA American Heart Association
ALT Alanine aminotransferase
AMI Acute m yocardial infarction 
AP Alkaline phosphatase
APCC Activated prothrombin complex concentrate
aPTT Activated partial thromboplastin time
ARC Academic Research Consortium
ASA Acet ylsalicy lic acid
ASO Antisense oligonucleotide
AST Aspartate aminotransferase
AUC Area under the curve
AXIA Activated Factor XIa activity
AxMP Auxiliary  medicinal product
BARC Bleeding Academic Research Consortium
BID Twice a day , Bis in die
BL Baseline
BMS Bristol -Myers Squibb
BP Blood pressure
BUN Blood urea nitrogen
CABG Coronary  artery  by[CONTACT_55911]. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  82of 86
CHMP Committee for Medicinal Products for Human Use
CK Creatinine kinase
CL/F Apparent oral plasma clearance
Cmax maximum observed concentration reached after administration
CONSORT Consolidated Standards of Reporting Trials
CRF Case report form
CSR Clinical study  report
CT Computed tomograph y
CTFG Clinical Trial Facilitation Group
CV Cardiovascular
CYP3A4 Cytochrome P450, family  3, subfamily  A, pol ypeptide [ADDRESS_61071]
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  83of 86
IB Investigator’s brochure
ICF Informed consent form
ICH International Council for Harmonization
IDMC Independent data monitoring committee
IDMS Isotope dilution mass spectroscop y
IEC Independent Ethics Committee
IMP Investigational medical product
IND Investigational New Drug
INN International non -proprietary  name
[CONTACT_55914] y on Thrombosis and Hemostasis 
IR Immediate -release
IRB Institutional Review Board
ISTH International Society on Thrombosis and Hemostasis
ITT Intent -to-treat
IV Intravenous(l y)
IVRS/I WRS, I xRS Interactive Voice/Web Response Sy stem
LDH Lactate deh ydrogenase
LDL Low-densit y lipoprotein
LSH Life Science Data Hub
LV Left ventricular
MCH Mean corpuscular hemoglobin
MCV Mean corpuscular volume
MD Medical doctor
MD / MDE Multiple dose/ multiple dose escalation
MDRD Modification of Diet in Renal Disease
MedDRA Medical Dictionary  for Regulatory  Activities
MI Myocardial infarction
MRI Magnetic resonance imaging
N Total number of participants
NA Not applicable
NIHSS National Institutes of Health Stroke Scale
NJ New Jersey
NOAC Non-Vitamin K oral anticoagulant
NSAID Nonsteroidal anti -inflammatory  drug
NT-proBNP N-terminal pro B -type Natriuretic Peptide
OD Once a day
P2Y 12 Gi-coupled platelet receptor for adenosine diphosphate
PCI Percutaneous coronary  intervention
PD Pharmacod ynamic(s)
PK Pharmacokinetic(s)
PT Prothrombin time
QC Quality  control
RAAUC Accumulation ratio for AUC
RACmax Accumulation ratio for C max
RAVE Data collection tool
RBC Red blood cell (count)
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  84of [ADDRESS_61072] Upper limit of normal
US/[LOCATION_003] [LOCATION_002]/[LOCATION_002] of America
VKA Vitamin K antagonist
VTE Venous thromboembolism
vWF Von Willebrand Factor
W Week
WBC White blood cell (count)
WOCBP Woman of Childbearing Potential
11. References
Adams HP, Jr., Bendixen BH, Kappelle L J, Biller J, L ove BB, Gordon DL, et al. 
Classification of subty pe of acute ischemic stroke. Definitions for use in a multicenter 
clinical trial. TOAST. Trial of Org [ZIP_CODE] in Acute Stroke Treatment. Stroke. 1993 
Jan;24(1):35-41.
Banks J L, Marotta CA. Outcomes validity  and reliability  of the modified Rankin scale: 
implications for stroke clinical trials: a literature review and s ynthesis. Stroke. 
2007;38(3):1091-6.
Brott T, Adams HP, Jr., Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of 
acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864 -70.
Chen Z, Seiffert D, Hawes B. Inhibition of Factor XI activity  as a promising antithrombotic 
strategy . Drug Discov Today . 2014 Sep;19(9):1435-9.
Ches ebro JH, Knatterud G, Roberts R, Borer J, Cohen L S, Dalen J, et al. Thromboly sis in 
Myocardial Infarction (TIM I) Trial, Phase I: A comparison between intravenous tissue 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  85of 86
plasminogen activator and intravenous streptokinase. Clinical findings through 
hospi[INVESTIGATOR_2345]. Circulation. 1987 Jul;76(1):142-54.
Coutts SB, Wein TH, L indsay  MP, Buck B, Cote R, Ellis P, et al. Canadian Stroke Best 
Practice Recommendations: secondary  prevention of stroke guidelines, update 2014. 
Int J Stroke. 2015 Apr;10(3):282-91.
Duga S, Salomon O. Congenital factor XI deficiency : an update. Semin Thromb Hemost. 
2013 Sep;39(6):621-31.
Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ, et al. Embolic 
strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 
2014 Apr;13(4):429 -38.
Johnson CO, Nguy en M, Roth GA, Nichols E, Alam T, Abate D, et al. Global, regional, and 
national burden of stroke, 1990 -2016: a sy stematic anal ysis for the Global Burden of 
Disease Study  2016. The L ancet Neurology . 2019;18(5):439-58.
Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al. Ticagrelor 
versus Aspi[INVESTIGATOR_55858]. N Engl J Med. 2016 Jul 7;375(1):35-43.
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit R A, Elm JJ, et al. Clopi[INVESTIGATOR_55859] -Risk TIA. N Engl J Med. 2018 Jul 
19;379(3):215 -25.
Kaatz S, Ahmad D, Spy ropoulos AC, Schulman S, Subcommittee on Control of A. Definition 
of clinically  relevant non- major bleeding in studies of anticoagulants in atrial 
fibrillation and venous thromboembolic disease in non- surgical patients: 
communication from the SSC of the I STH. J Thromb Haemost. 2015 
Nov;13(11):2119-26.
Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI , Ezekowitz MD, et al. 
2014 AHA/ASA Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Jul;45(7) :2160 -236.
Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu 
DC, et al. Management of severe perioperative bleeding: guidelines from the European Society  of Anaesthesiology . Eur J Anaesthesiol. 2013 Jun;30(6):270-382.
Lansberg MG, O'Donnell MJ, Khatri P, L ang ES, Ngu yen-Huynh MN, Schwartz NE, et al. 
[ADDRESS_61073] Antithrombotic and thromboly tic therapy  for ischemic stroke: 
Antithrombotic Therap y and Prevention of Thrombosis, 9th ed: American College of 
Chest Phy sicians Evid ence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141([ADDRESS_61074]):e601S -e36S.
Levey  AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using 
standardized serum creatinine values in the modification of diet in renal disease stud y 
equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247 -54.
Ling G, Kagdi H, Subel B, Chowdary P, Gomez K. Safet y and efficacy of factor XI (FXI) 
concentrate use in patients with FXI deficiency : a single -centre experience of 19 y ears. 
Haemophilia. 2016 May ;22(3):411 -8.
Lyden P, Brott T, Tilley  B, Welch KM, Mascha EJ, L evine S, et al. Improved reliability  of the 
NIH Stroke Scale using video training. NINDS TPA Stroke Study  Group. Stroke. 
1994;25(11):2220-6.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 
Guidelines for the Earl y Management of Patients With Acute I schemic Stroke: A 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  86of 86
Guideline for Healthcare Professionals From the American Heart 
Association/American Stroke Association. Stro ke. 2018 Mar;49(3):e46 -e110.
Pugh RN, Murray -Lyon IM, Dawson J L, Pi[INVESTIGATOR_9051], Williams R. Transection of the 
oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646 -9.
Quan H, Zhang D, Zhang J, Devlamy nck L. Analysis of a binary  composit e endpoint with 
missing data in components. 2007;26(26):4703-18.
Ringleb PA, Bousser M- G, Ford G, Bath P, Brainin M, Caso V, et al. 2008 European Stroke 
Organization (ESO) Guideline for Management of Ischaemic Stroke and Transient Ischaemic Attack. 2008.
Sharma M, Hart RG, Connolly  SJ, Bosch J, Shestakovska O, Ng KKH, et al. Stroke Outcomes 
in the COMPASS Trial. Circulation. 2019 Feb 26;139(9):1134-45.
Sharma M, Hart RG, Smith EE, Bosch J, Yuan F, L ，D, et al. Results of the cardiovascular 
outcomes for people using anticoagulation strategies (COMPASS) randomized trial MRI  and neurocognitive deterioration substudy  (COMPASS MIND) European Stroke 
Journal. 2019;4(1_suppl):779-89.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Univ ersal 
Definition of My ocardial I nfarction (2018). J Am Coll Cardiol. [ADDRESS_61075] 
30;72(18):[ADDRESS_61076] on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology  Task Force on 
Expert Consensus Decision Pathway s. J Am Coll Cardiol. 2017 Dec 19;70(24):3042 -
67.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. I nterobserver agreem ent 
for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604- 7.
Wang Y, Wang Y, Zhao X, L iu L, Wang D, Wang C, et al. Clopi[INVESTIGATOR_55860]. N Engl J Med. 2013 Jul 4;369(1):11 -9.